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 Various biomolecules and cell types have been demonstrated to have the capacity to form 
plasmonic gold nanoparticles when chloroauric acid (HAuCl4) is introduced.We have 
demonstrated the capacity and utility of nanoparticles generated from endogenous biomolecules 
through three examples which can potentially be applied to multitudes of applications (1) Through 
a point of care reactive gel, acting as a scaffold for ionic gold (Au3+) capable of sensing reductive 
biomolecules presented in high concentrations during eye injury; (2) The generation of gold 
nanoparticles intrecellularly for enhanced phenotype observation of the cell combined with 
therapeutic potential; and (3) A simplistic, single-step means of generating gold nanoparticles 
functionalized with whole cell membrane which imparts minimal impact on biomolecule integrity. 
From this body of works we have demonstrated that multitudes of endogenous biomaterials have 
the capacity to reduce and form nanoparticles by variety of mechanisms which can directly be 
applied to sensing pathological states, applying therapy, as well as a means for improvement on 
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1.1 MODERN DISEASE AND CANCER 
As society evolves and changes, so do the pathologies that impact it. In 1910, 46% of deaths were 
from infectious disease compared with 3% (from infectious disease) in 2010.1,2 This reduction in 
mortality via infectious disease can be attributed to many biomedical advancements. Because of 
these advancements, the average lifespan has increased steadily over the past hundred years with 
the mortality rate in decline. In modern society, the leading causes of mortality are largely lifestyle, 
age, genetically and environmentally driven. Of these modern diseases cancer receives a large 
spotlight due to the inherent complexity of the disease arising from mutations of normal cell 
behavior. The variety in cancers, which are heterogeneous by nature, can not only vary from person 
to person, but even regionally within the same tumor mass.3–5 Current therapeutic approaches 
against cancer are largely developed specifically against cancers characterized as arising from a 
specific tissue or organ type, however, due to the nature of the disease (as it arises from 
aggregations of mutations), there can exist multiple varieties throughout ‘individual’ cancers. 
Approaches to therapy which target individual pathways or targets with treatments specific for 
those pathways/targets are in some cases unable to provide long-term benefit in reducing the tumor 
size.6,7 This approach, wherein therapeutics aim toward a single process, target, and or pathway is 
a binary approach to spectral issue. To overcome this heterogeneity of disease, the concept of 
personalized medicine has emerged wherein specific therapeutics are paired to disease based on 




   
1.2 PERSONALIZED MEDICINE 
Many of these modern diseases are heterogeneous by nature – especially cancer which arises from 
mutations and various malfunctions of normal cellular processes. Because of this, cancers can have 
variety between patients, organ systems, and even regionally within a ‘single’ tumor. Because of 
this heterogeneity of the disease, cytotoxic drugs will have varying degrees of efficacy. This 
intertumoral variation compounds with the variety found between human people adding layers of 
complexity to an already complex problem.  
“It is more important to know what sort of person has a disease than to know what sort of 
 disease a person has.” - Hippocrates     
This concept that disease can behave differently between persons is not of recent novelty; 
Hippocrates, the “Father of Medicine” knew this and now (twenty centuries later) its importance 
is reemerging. Personalized medicine can exist in many forms because at different levels of group 
identity applications can be more or less appropriately applied. This idea that group identity can 
be involved for personalization of medicine/ therapeutics can be applied at the levels of species, 
sex, age, region, vocation and genetically. Different groups with different identities are products 
of different lifestyles, environments, and will be afflicted differentially and in turn should be 
treated non-uniformly to combat those diseases when it is appropriate to do so. For therapeutic 
drug development, pre-clinical studies are often conducted in non-human mammals because 
primary human testing is not be feasible. Special care and understanding of the disease must be 
made to choose the animal model which the pathology is appropriately related to the human 
disease. Therapeutics developed for humans using an animal model can only be considered 
appropriate if the animal model is similar to the human pathology. There is variety between human 
and non-human mammals, however, not until the therapeutic has successfully passed pre-clinical 
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trials and enters clinical trials can these differential therapeutic effects be uncovered. It would seem 
intuitive to choose the therapeutic developed for humans opposed to any other species, however, 
we must acknowledge that most, if not all of these therapeutics were initially developed and 
optimized within another specie. At the level of sex variation, attention to variability began at only 
the reproductive organ level. Practically all of early medical knowledge was developed for men 
(and male animals) and by men and only recently has this began to shift to include women’s health. 
Now, the NIH requires that biological sex be considered as a variable for in order to receive 
funding (except for sex specific diseases such as prostate and ovarian cancer). For age variation 
there is pediatric, family, and geriatric medicine for three stages of aging health throughout life. 
We understand that some vocations place people at higher risk for certain disease. Occupational 
disease has appeared in a variety of scenarios as black lung (coalworkers’ pneumoconiosis), 12–
14squamous cell carcinoma (chimney sweeps’ carcinoma),15–17 and others. Humans, with 
incredible variety, now with an ever growing population provide difficulty in providing medical 
therapy as pathological states arise from irregular behavior in an irregular backdrop system. From 
the many means and groupings for potentially personalizing therapeutics we now distill these 
varieties between persons to the genetic level to uncover how the patients genetic code may 
contribute to that person’s illness and to use this information to appropriately match therapy.9–11 
Specifically to cancer optimization of the application of these cytotoxic drugs must be matched 
with pathologies and mutations in normative processes that the cancer possesses. A large portion 
of this matching can be ascertained through genomic inquiry (for cancers that originate from 
genomic mutations), and this methodology will continue to improve as collections of genomics 
data increases with computational power to interpret it. However, many cancers are not 
genomically homogenous, which would result in mixed results and the bulk of the tumor may 
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change throughout treatment. To apply therapeutics or diagnostics which can adapt to the patients 
pathology in real time (or near real time), would be the full actualization of the field of personalized 
medicine. To preamble this lofty ultimate personalization of adaptable therapeutics and diagnostics 
has been with the notion of ‘theranostics’ (combination of therapeutics and diagnostics). This 
combination has enabled a means of observing the efficacy of therapeutics and in turn better 
optimization of their design and application. 
 
1.3 NANOMEDICINE BASED THERANOSTICS 
Nanoscaled materials have enabled many theranostic queries into biomedical applications.18–23  
Nanoscaled materials possess unique properties compared to bulk materials in terms or catalytic, 
optical, and magnetic to name a few; these properties as well as their high surface area to volume 
ratio have enabled nanoscaled materials and nanoparticles unique applications for biomedicine.24–
26 The size scale of 'nano-' is the same size scale wherein biochemical reactions occur and the same 
scale which visible light wavelengths. This similar size scale allows nanomaterials and 
nanoparticles to effectively interact with and potentially disrupt these similarly scaled processes, 
if targeted correctly. This "targeting" of nanoparticles to specific processes is no simple task. 
however, facing barriers such as the skin, mucous, immune system, cell membrane, and navigation 
to name a few. Initially, an appropriate materal must be selected either being biodegradable 
(metabolized in vivo without negative impact), bioinert (not able to be metabolized and without 
negative imact), or it must be sufficiently coated to both protect the biological system and preserve 
the desirable properties of the chosen materal. Many different materials exist for biomedical 
nanoparticle applications, and are generally divided into categories of soft (polymers, lipids, and 
organic compounds) and hard nanoparticles (metals, and inorganic compounds). Some of these 
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materials may have inherent properties, which are beneficial or potentially beneficial for imaging 
and/or therapeutic application such as magnetic (Fe3O4)27–29 or optical (Au, Ag, Cu)30–33 while 
others may simply act as containers or vehicles for therapeutics and or  diagnostic imaging contrast 
enhancing agents. When choosing the material best suited for the desired application additional 
consideration must be given to the shape, size, and surface-coating on the chosen nano-vector.30,34–
38 The factors of shape, size, and surface-coating can impact physico-chemical properties, 
degradation rate, biodistribution, pharmico-kinetics, cellular internalization, and even the unique 
properties afforded by the chosen material's characteristics. 20,36,39–46Therein lies the difficulty of 











2.1 GOLD NANOPARTICLES 
Gold nanoparticles have existed and been utilized since mideval times (as colorand for stained 
glass), however, our capacity to understand their nanoscale phenomena has only been made 
available more recently. Gold itself has been sought after throughout human culture, initially for 
coinage and jewlery as a rare commodity, after the discovery of electricty gold was found to be an 
excellent conductor, and was one of the first materials available as dental implants.  As 
nanoparticles, gold has been extensively researched and applied due to their simplistic, tunable 
chemistry to control and modify size, morphology, and surface functionality; combined with their 
size-morphology-dependent electromagnetic properties.36,47–52 These size and morphology 
depenendent optical are only observed in plasmonic metals (Au, Ag, and Cu) and only in the 
nanoscale.31–33,53 Surface plasmon resonance (SPR) in metallic nanoparticles, originate from 
coherent oscillations of conduction electrons and electromagnetic waves propagation at the planar 
interface of dielectric-conducting media.54–58 SPR properties do not degrade over time and are 
dependent upon the nanoparticle shape, size and on the refractive index of their surroundings. 
These unique plasmon-optical properties, have been utilized as combined diagnostic and 
therapeutic agents as pre-clinical cancer cell treatments.20,40,59,60 The process for gold nanoparticle 
formation, involves at minimum, chloroauric acid as a precursor material and a reducing agent for 
catalyzing the reductive nucleation. Variations of the reducing agent molecule, and reaction 
conditions (e.g. pH, temperature, incubation time), will result in different morphologies, sizes, and 
functionalities of resulting nanoparticles. The ionic precursor can be readily reduced by a variety 
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of functional groups. Many works have utilized natural products, which can have innate targeting 
and functional properties, for gold nanoparticle synthesis.  
 
2.2 MEMBRANE WRAPPED NANOPARTICLES AND LIVING THERAPEUTICS 
Many of the most productive therapeutic applications are derived from, inspired by, or isolated 
from natural products. Many of these compounds have been developed through thousands of years 
of evolutionary pressures fulfilling a particulary niche utility.  Due to the fact that this evolutionary 
process for developing biomolecules results in highly effacacious and specific behavior, there are 
drives to isolate 'new' unknown compounds, reapply compounds/structures/chemicals already 
known, or generate novel structures based on an accelarated evolutionary process (termed, 
"directed evolution").61–63 This biomimetic strategy wherein tools extracted, modified, or inspired 
by nature has also seen application in nanomedicine.38,64–70 Some of these strategies involve the 
attachment of biologically derived molecules to the surface of nanoparticle vectors, wrapping the 
nanoparticle with biologically derived products, and/or collecting naturally occuring nanoparticles 
and repurposing them and or modifying them for therapeutic applications. Strategies wherein, 
biomolecules combined with nanovectors for targeting (with receptor-binder molecules), to induce 
therapeutic effect (affector molecules), or to evade immune response. These biomolecules that are 
either used for targeting, therapy, or evation can be combined with nanoparticles that either have 
innate imaging contrast enhancement properties or enable the combination with imaging contrast 
enhancement molecules (typically inorganic and not biologically derived). Some of the most 
advanced strategies for both targeting nanovectors to pathology, neutralizing toxins, and for 
evading the immune system utilize whole cell-membrane for nanoparticle 
functionalization.38,65,67,68,70–75 This strategy, wherein whole cell membrane is utilized for 
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functionalization takes advantage of the complexity of the protein-lipid content and organization 
which cells normally used for communication and interaction (instilling these capacities to 
nanoparticle vectors). This strategy of using cell membrane to functionalize nanovectors coopts 
the biological processes of which activity is located within the membrane. These membrane 
derived processes are namely communication, migration, and adhesion.68,70,76–83 This strategy of 
utilizing complex membrane components to determine vector behavior are utilized by bacteria, 
viruses, and cells. When these nanoparticles are coated with whole cell membrane they can exhibit 
behaviors of the membrane-derived cells as psuedo-living therapeutics. Additionally to this there 
are nanovectors which exist in nature that navigate and impart biological effects on cells they 
interact with. These biological nanovectors include but are not limited to viruses and exosomes.64  
 
2.3 GOLD NANOPARTICLE GENERATION WITH ENDOGENOUS BIOMOLECULES 
Gold nanoparticles are easily reduced from chloroauric acid by a myriad of reductive molecules, 
and the qualities of these resultant nanoparticles are reflective of the environments that caused 
them to form.48,50,51 From this knowledge we can posit that nanoparticle formation can in turn 
report the synthetic conditions. If we use biological materials and environments for this reduction 
and formation of gold, therein, we can use the resulting nanoparticles to report the conditions of 
the biological materials and environment. Proteins, nucleic acids, sugars, and lipids have all as 
some point been utilized as reductive molecules for the formation of biologically conjugated gold 
nanoparticles.84–87 These biologically derived materials contain functional groups such as  
hydroxyls, carboxylic acids, thiols, amides, and amines which have all been identified as functional 
groups with varied capacity to form nanoparticles for benchtop synthesis. We hypothesized that 
the concentration of these functional moieties provided by endogenous biomolecules would offer 
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an attractive potential for a pathologically dependent nanoparticle synthesis. We demonstrate the 
capacity and utility of nanoparticles generated from endogenous biomolecules through three 
general examples which can potentially be applied to multitudes of applications 
1) Through a point of care reactive gel, acting as a scaffold for ionic gold (Au3+) capable of 
sensing reductive biomolecules presented in high concentrations during eye injury. 
2) The generation of gold nanoparticles intrecellularly for enhanced phenotype observation 
of the cell combined with therapeutic potential.  
3) A simplistic, single-step means of generating gold nanoparticles functionalized with whole 





   
CHAPTER 3 
RESULTS AND DISCUSSION 
 
3.1 IN SITU GOLD NANOPARTICLE FORMATION FOR BIOMOLECULE DETECTION 
AND QUANTIFICATION 
Herein, we describe a new reactive sensing material, called ‘OjoGel’, composed of ionic gold 
interspersed through agarose gel scaffolding (Scheme 1). Our hypothesis, is that upon interaction 
with reductive molecules the OjoGel will undergo colorimetric changes through plasmonic 
nanoparticle formation in a quantifiable manner dependent on the concentration of the reductant 
molecules. To test the application of the OjoGel, we utilized ascorbic acid (AA) as a potential 
endogenous reductant due to its reductive capacity (E0 = +0.06 V,  25 C).88 The concentration of 
AA within the external ocular tear film (23 ± 9.6 µmol/L) is magnitudes lower than AA 
concentration within internal aqueous humor (1049 ± 433 µmol/L),  and as such, pathologically 
elevated levels of AA within the tear film that result from a direct leak of aqueous humor into the 
tear fluid can serve as a surrogate biomarker of anterior scleral or corneal wound integrity. The 
aqueous humour is a clear, water-like, low-protein containing fluid that is secreted from the ciliary 
epithelium. Aqueous humor is continuously produced within the anterior chamber of the globe, 
therefore, if the integrity of the anterior globe is disturbed, the concentration of AA in the tear film 
will rise due to direct contamination of the tear fluid with aqueous humor. These variations of 
endogenous reductant concentrations between intact tear film and aqueous humor (as AA) 
demonstrate one of many potential utilities for our OjoGel biosensor. We have characterized a 
quantifiable colorimetric relationship between OjoGel treatments of AA (in solutions of varied 
complexity) and resulting Red-Green-Blue (RGB) values acquired from mobile phone images 
(with Pixel Picker® application). In demonstrating the capacity of the OjoGel to determine AA 
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concentration in water, contrived tear film, and clinical samples of aqueous humor, we have 
confirmed that the OjoGel can be utilized to detect ocular integrity through measuring the 
variations in AA concentration of patient tear film samples. This increased level of AA could be 
tested using OjoGel tubes and concentrations determined using simple Pixel Picker® mobile phone 
application. Chapter 3.1 contains previously published data.89 
 
  
Scheme 1 A schematic describing the correlation of color codes with AA concentration from OjoGels reduced with 
different tear film samples. (A) Prepared OjoGel tubes and chemical composition, (B) Reduced gold chloride to 
gold nanoparticles in OjoGel with changed color due to generated plasmon formation and (C) intensity of 
plasmonic absorption (color) correlating with AA concentrations from different standards. 
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3.1.1 FEASABILITY OF PLASMONIC GOLD NANOPARTICLE GENERATION VIA 
ACTION OF ASCORBIC ACID AND AQUEOUS HUMOR 
Aqueous humour contains a wide variety of surfactants as well as containing high concentrations 
of AA, which can reduce gold (III) as an endogenous reductant to produce gold nanoparticles.90 In 
order to determine the feasibility of designing a plasmonic sensor based detection of diffuse AA 
content in controlled solutions (containing only AA and water) with and more complex clinical 
samples required an initial screening. To determine this feasibility, we admixed ionic gold (Au3+) 
with either clinically aquired aqueous humor or ascorbic acid at a concentration of 1 mM dissolved 
in deionized water (DI-H2O). From these two mixed solutions, we observed colorimetric reactions 
occur; as the solution containing aqueous humor went from yellow to red with UV-Vis absorbance 
peak at ~540 nm (characteristic of gold nanoparticles), and from yellow to clear (with visible 
brown aggregates) with an absorbance spectra identical with pure water from the solution with 
isolated ascorbic acid (Figure 1D). Through dynamic light scattering, we found that the mixture 
with isolated AA resulted in entities of sizes much larger (>500 nm) than those produced with 
aqueous humor (~40 nm) (Figure 1A). However, by utilizing transmission electron microscopy 
(TEM) we found that these larger entities were aggregations of nanoparticles ~40 nm in diameter 
(Figure 1B). From this information, we can conclude that AA alone is sufficient to reduce the 
ionic gold but not to stabilize the nanoparticles enough to keep them segrregated. Aqueous humor,  
containing both reductant and stabilizing molecules resulted in colloidally stable nanoparticles 
(~30 nm anhydrous diameter through TEM) without aggregation (Figure 1C).  These results, 
indicating that gold nanoparticle reduction occurs via AA in pure solution and as component of 
aqueous humor were further corroborated via surface enhanced Raman spectroscopy. To collect 
enhanced Raman spectra, mixed solutions of ionic gold with AA in pure solution and as component 
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of aqueous humor were pipetted up and down to mix before being pipetted onto glass slides. 
Solutions on these slides were dried for >24 hr before Raman measurements were collected using 
a 635 nm laser.  For the mixture containing only ascorbic acid and ionic gold we see enhancement 
of ascorbic acid signature without interference from other components (Figure 1E).  This 
enhancement found in the samples containing only AA and ionic gold is due to the nano-scaled 
features of the nanoparticle aggregates acting as “nano-antennae”. If we compare this spectra with 
the mixture containing aqueous humor, we are able to observe much greater signal noise, as well 
as increase in overall Raman signal. This increase in intensity of Raman signal is causal of there 
Figure 1 (A) Hydrodynamic diameter of gold nanoparticles reduced with aqueous humor (blue) and asorbic acid 
(red) 250 µM. (B) TEM of gold nanoparticles reduced with asorbic acid (50 nm scale bar) 250 µM. (C) TEM of 
gold nanoparticles reduced with aqueous humor (50 nm scale bar). (D) UV-Vis spectra of gold nanoparticles 
reduced with aqueous humor (blue) and asorbic acid (red) 250 µM. (E) Raman spectra of gold nanoparticles 
reduced with aqueous humor (blue) and asorbic acid (red) 250 µM. 
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existing a larger population of nanoparticles whose plasmonic absorbance matches the Raman 
laser wavelength. The Raman signal noise is due to the increased complexity of the mixture 
resulting from multiple molecules (not just AA) recieving plasmonically enabled Raman signal 
enhancement. These findings, support the notion that bodily fluids containing endogenous 
reductants (such as AA) that can reduce ionic gold, forming plasmonic gold nanaoparticles, could 
potentially be measured in quantifiable manner through optical colorimetric means.   
 
3.1.2 SYNTHESIS OF OJOGEL AND DETECTION OF ASCORBIC ACID VIA OPTICAL 
DIFFERENTIATION  
It was established that gold chloride could be reduced with ophthalmic fluids known to contain 
high AA concentration and AA alone, however, AA was not effective in producing colloidally 
stable gold nanoparticles without stabilizing agents. To address the issue of nanoparticle 
aggregation in technical grade standards  (solutions free of non-analyte biomolecules which are 
necessary for calibrations) we embedded ionic gold within an agarose gel scaffold, termed 
‘OjoGel,’ as a plasmonic sensing platform where AA (or any other endogenous biological 
ruductant) could be optically quantified (Figure 2A and B). To prepare the OjoGel, 1 ml of 30 
mM gold (III) chloride solution was admixed with 4 ml of 4% (w/v) agarose in de-ionized water 
(DI-H2O). The mixtures were microwaved for 90 seconds (high power setting, using a Sunbeam 
microwave), until solution was homogenous with care to ensure that the ionic gold not be 
microwaved for too long (causing auto-reduction). As the mixture became homogenous, it was 
poured and cast in 0.6 mL centrifuge tubes for convenience (however the OjoGel can be cast into 
any number of shapes/ forms). Once cooled and solidified, the cast OjoGels were stored at 4C 
prior to experimental measurement (Figure 2A). To activate the OjoGel as a sensor for 
biologically endogenous reductants (AA), treatments were applied through channels made with 
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glass capillary tubes. Upon treatment of OjoGel with AA or aqueous humor containing AA, the 
color of the gel would change to a mahogany/orange-brown due to an increased localized 
nanoparticle formation at the treatment site (Figure 2B) and could be correlated with color codes 
(Figure 2C). OjoGel sample (Figure 2A) was incubated (5-30 minutes) with different AA and 
AH samples generating gold nanoparticles and related plasmonic color (Figure 2B). Here spot 1-
8 represent various volume and concentrations of AA in standard solution as spot 1 for 0 mM (5 
µL), spot 2 for 1 mM (5 µL),  spot 3 for 1 mM (5 µL) and spot 4 for 100 mM (20 µL) while AA 
in different AH samples (20 µL) as spot 5 for AH1, Spot 6 for AH2, Spot 7 for AH3 and Spot 8 
for AH4. This plasmonic nanoparticle formation resultant of treatment was confirmed through 
TEM images of nanoparticles extracted from OjoGel spots from AA (1 mM; Spot 2) (Figure 2C) 
and AH incubation (AH1; Spot 5) (Figure 2D) dissolved with sodium hypochlorite solution.  With 
titrated amounts of AA (2000, 1000, 500, 250, 100 and 50 µM). To determine this colorimetric 
Figure 2 Characterization of prepared OjoGel (A) before and (B) after reduction with AA concentrations. Spot 
1-8 represent various volume and concentrations of AA in standard solution Spot 1: 0 mM (5 µL); Spot 2: 1 mM 
(5 µL); Spot 3: 1mM (5 µL) and Spot 4: 100 mM (20 µL) and AA in different aqueous humour samples (AH; 20 
µL) as Spot 5: AH1; Spot 6: AH2; Spot 7: AH3 and Spot 8: AH4. Transmission electron microscopy images 
from reduced OjoGel obtained from (C) AA (1 mM; Spot 2). Inset represents calculated Feret diameter of the 
jelly fish structure and (D) AH incubation (AH1; Spot 4). Inset represents TEM image of one unit of reduced 




   
relationship, 50 pictures were captured of each titrated AA treatment using a camera phone (Apple 
iPhone 7 (12 MP, f/1.8, 28mm, 1/3", phase detection autofocus, OIS, quad-LED dual-tone flash), 
and the average RGB values were numerically determined using the Pixel Picker® application 
(available from the Apple App Store™). After finding a logarithmic colorimetric relationship 
between AA (dissolved in DI-H2O) and RGB values determined with Pixel Picker
®, we then aimed 
to find if this relationship would be maintained in more complex solutions (similar to clinical 
samples). To discover if this colorimetric relationship would be maintained in more complex 
mixtures, contrived tear film (CTF) was used in place of DI-H2O for titrated treatments of identical 
AA concentrations. The contents of CTF, being similar in content to biological tear film, provided 
an outlet for realistic testing conditions for our OjoGel without the volume limitations and 
variability found in clinical samples.  From these treatments with titrated amounts of AA, we found 
a logarithmic relationship between the R hexadecimal values of the OjoGel and the AA 





   
  
Figure 3 Hexadecimal R values from photographed OjoGels as a function of ascorbic acid concentration (50 – 
2000 µM) in water (A) (n=50 images) and (50 – 2000 µM) contrived tear film (C) (n=50 images). Hexadecimal 
R values from photographed OjoGels as a function of ascorbic acid concentration in water (B) (n=50 images) and 




   
3.1.3 DETECTION OF ASCORBIC ACID IN AQUEOUS HUMOR AND VALIDATION 
AGAINST ELISA 
To validate OjoGel as a sensor for the detection of AA in clinically relevant settings, aqueous 
humor samples were clinically obtained and then tested for AA using both OjoGel and ELISA 
(Figure 4A-C). AA concentration of five clinical aqueous humor samples were measured in 
duplicate via ELISA. It is important to note, that ELISA measurements were only able to be 
collected in duplicate due to the small sample volume of clinically acquired aqueous humor 
(<3µL). This is an inherent limitation to the capabilities of ELISA in detecting AA in clinically 
collected samples of aqueous humor from aqueous paracentesis (this procedures limits collection 
to average around 1-2 µL of fluid due to physiological restrictions in volume of the anterior 
chamber), but ELISA is still currently considered best practice, and standard-of-care. The 
calibration of the ELISA against AA was performed in duplicate by dissolving known 
concentrations of AA in DI-H2O. The AA levels in aqueous humor samples collected from subjects 
# 1, 2, 3, 4 and 5 are 4.079, 2.247, 5.119, 2.792, and 14.623 nM, respectively. Aqueous humor 
Figure 4 (A) Concentration of ascorbic acid in standard samples and correlation with absorption intensity at 490 
nm. (B) Concentration of ascorbic acid in clinical aqueous humor samples as calculated from Hexadecimal R values 
from photographed OjoGels as a function of ascorbic acid concentration in water (n=25 images). AA concentrations 
of 4.079, 2.247, 5.119, 2.792, and 14.623 nM are obtained in the aqueous humor samples # 1, 2, 3, 4 and 5 
respectively (C) R Hexadecimal values from photographed OjoGels as a function of ascorbic acid concentration in 




   
samples remaining after ELISA measurement were used to treat OjoGel sensors and for each of 
these treatments 50 images with corresponding RGB values were collected. The red (R) 
hexadecimal value for the OjoGel treated with clinical samples had an apparent logarithmic 
relation to concentration of AA (as determined by ELISA). A comparison of two methods OjoGel 
and ELISA was done to demonstrate the accuracy (% error) based on the AA level determined in 
the aqueous humor samples. When we used the red (R) hexadecimal values of the OjoGel treated 
with clinical samples to back calculate the AA concentration using the relationships calibrated in 
water and contrived tear film, we found a logarithmic relationship within our testing range, 
however, at concentrations higher than those obtained via ELISA. The two methods co-related 
with regression value (R2 = 0.8995) and showed strong validity of the proposed OjoGel for the 
detection of AA concentration (Figure 4C).  
 
3.1.4 COLOR CODE RINGS AND SIMULTANEOUS CALCULATION OF AA 
CONCENTRATION IN AQUEOUS HUMOR 
Prepared color rings with known AA concentration color (Figure 5B) were decorated around the 
neck of OjoGel sample tubes (Figure 5A) before capillary tubes (Figure 5C) mediated transfer of 
AA samples (Figure 5E-I) on top of OjoGel tubes. Within two min of incubation a color change 
was noticed on the top of the OjoGel surface. Pixel Picker®app was used to catch the color and 
correlated with color codes on rings present around the neck of OjoGel tubes. A range of 50 to 
2000 µM of AA was reported in different clinical AH samples. 
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3.1.5 SPECIFICITY AND SENSITIVITY OF OJOGEL 
In our experiments, two other major components of aqueous humor, L-lactic and sialic acid, were 
chosen to investigate the specificity of the OjoGel. In a typical experiment, 2000 µM AA, L-lactic 
and sialic acid were added to the OjoGel material. It was observed that with the treatment of 
OjoGel with AA the color of the gel would change to a mahogany/orange-brown due to an 
increased localized nanoparticle formation at the treatment site but remained unchanged when 
treated with L-lactic acid and sialic acid (Figure 6A). To determine this colorimetric relationship 
again 25 pictures were captured of each titrated acid treatment using a camera phone, and the 
average RGB values were numerically determined using the Pixel Picker® application (available 





Figure 5 (A) OjoGel tube sample (i) without and (ii) with incubated AA (B) Color code ring with printed AA 
concentrations, (C) glass tubes for transferring AA samples on OjoGel tubes and (D-I) AA concentrations 




   
over other acids and the high specificity of the OjoGel is mainly due to the high reducing activity 
of AA. These results manifest that AA can be detected in tear film with high selectivity. To discuss 
the sensitivity of the OjoGel, we must first consider that since resulting colorimetric changes are 
logarithmically responsive to the concentration of endogenous reductant (AA) in both pure and 
complex solutions (Figures 3 and 4), that the sensitivity (RHex/[AA] (µM
-1)) of these 
measurements will be directly dependent on the treatment concentration (Figure 6B). This 
colorimetric relationship, is beneficial in that it is similarly logarithmically responsive like the 
human eye in perceiving light,91,92 in that it provides higher sensitivity between lower treatment 
concentrations, and that it is more able to detect lower concentrations of reductant in more complex 
solutions.  To calculate the sensitivity (µM-1) for each theoretical treatment concentrations, we 
took a first order derivative of the dose-response curves calibrated in water and contrived tear film 
from Figure 3. As the relationship between sensitivity (RHex/[AA] (µM
-1)) and AA concentration 
is inverse, we only need to calculate the detection limit in order to calculate the maximum 
sensitivity provided by our sensing material. To calculate the lowest theoretical detectable AA 
concentration, we would input the value of 255 = R into the logarithmic lines of best fit as 
calibrated in water and contrived tear film. After calculating the theoretical detection limit (Table 
Figure 6 (A) Specificity of OjoGel. Actual hexadecimal value of OjoGel and after treatment with L-lactic acid, 
Sialic acid, and Ascorbic acid.  These testing confirms that ascorbic acid can be detected in tear film with high 
selectivity. Statistical analysis was performed using ONE WAY ANOVA comparing OjoGel background 




   
1), we could also use this to calculate the maximum sensitivity (as described earlier). To determine 
the effective range of usable concentrations for our sensor, we needed to determine at what point 
we would consider the signal to be saturated (when the sensitivity is too low to differentiate 
between measurements). We arbitrarily set the saturation sensitivity as 0.2 µM-1, as the Pixel 
Picker® phone application cannot distinguish hexadecimal values with separation less than one. 
Having chosen this saturation sensitivity, we could then back-calculate the concentration of AA 
resulting in those sensitivities for both AA in tear film and water, and then use this to calculate the 





Parameters DI-H2O Contrived Tear Film 
Maximum Sensitivity (µM-1) 13.70 38.15 
Lowest Detectable Concentration (µM) 0.88 0.26 
Lowest Usable Sensitivity (µM-1)  0.2 0.2 
Signal Saturation Concentration (µM) 60.25 48.88 
Table 1 Sensitivity Parameters calculated using the R Hexadecimal values of AA obtained in both DI-H2O 




   
3.2 IN VIVO FORMATION OF THERANOSTICS VIA CELLULAR MECHANISMS 
Gold nanoparticles have been extensively applied for biological applications due to their 
simplistic, tunable chemistry to control and modify size, morphology, and surface functionality; 
combined with their morphology-dependent plasmonic absorption properties.31,32,93,94 Typically 
for gold nanoparticle formation, the process involves at the minimum, chloroauric acid as a 
precursor material and a reducing agent for catalyzing the reductive nucleation. Variations of the 
reducing agent molecule, and reaction conditions (e.g. pH, temperature, incubation time), will 
result in different morphologies, sizes, and functionalities of resulting nanoparticles.30,34,95,96 For 
biomedical applications, these variations in morphology, size and functionality on the nanoscale 
are deterministic for how the gold nanoparticles may be optimally applied as these properties are 
directly related to cellular internalization,97,98 biodistribution half-life,36,39 renal secretion,36,39,40,99 
and plasmon optical properties.30–32,34,93–96 Because of these plasmon-optical properties of gold 
nanoparticles, they are inherently theranostic; providing imaging contrast through NIR,100,101 
fluorescence,102,103 X-Ray,104,105 photoacoustic,106–108 and Raman enhancement;109,110 and acting 
as a vehicle to enhance ablative therapies for both  photothermal,111–113 and X-Ray radiation.114–
116 The bio-inertness of gold nanoparticles, as well as the diverse range of applicable reductant 
molecules, has allowed researchers to develop biomimetic gold nanoparticles utilizing proteins or 
other biomolecules as scaffolds for reduction of ionic gold to plasmonic.89,117–119 Through this 
approach, which utilizes biomolecules for reduction, there require no additional steps for 
bioconjugation as the reducing biomolecules remain strongly attached following the synthesis. If 
these gold nanosystems were generated intracellularly, utilizing phenotypically dependent cellular 
machinery, we could potentially sense said affecting phenotype through the resultant plasmonic 
properties. This capacity to generate gold nanoparticles via cellular biomolecules has been 
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demonstrated previously in mammalian cells.120–125 While the precise mechanism for this cellular 
bioreduction of gold nanoparticles is not fully understood, it is understood that these treatments 
negatively impact cell heath through cellular responses via shock and stress-related proteins,125  
decrease in viability,123,124 and even causing cell fixation.123 These previous works, wherein ionic 
gold is applied diffusely to generate gold nanoparticles via cellular mechanisms, could not easily 
be directly applied as cellular diagnostics or therapeutics, as the process is so deleterious and is 
not cell-specific. As such, this process of cellular bioreduction forming gold nanoparticles has been 
marketed as a means for generating biomimetic and biofunctional gold nanoparticles which can 
then potentially be applied to physiological systems. We believe that if ionic gold were deployed 
to cells in discrete nanoscaled packets, this could reduce the concentration of gold necessary for 
this reduction, as well as the time frame and overall impact on cell health. Here we demonstrate a 
simplistic delivery vehicle for deploying ionic gold, demonstrating intracellular nanoparticle 
formation within a time span 20 hours less than previous reports, at concentrations less than 1/4000 
of previous applications, in full cell media. Additionally, we identify proteins and their respective 
subcellular locations involved in this cellular bioreduction of gold nanoparticles, providing insight 
into the potential reduction pathway as a sequential process wherein proteins are accumulated 
through their binding/reduction of gold as part of the delivery vehicle. This process, wherein 
sequential and progressive gold nanoparticle reduction occurs, primarily via excreted/ secreted 
proteins in the extracellular space and finally within the nucleus for terminal reduction, has 
minimal impact on protein expression/integrity and because of these attributes has strong potential 
for theranostic application. We demonstrate an application of this theranostic potential through a 
MCF-7 cancer xenograft model wherein fluorescent and photothermally active nanoparticles are 
simeoultaneously formed intracellularly to remediate cancer xenografts. 
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3.2.1 AU-DELIVERY VEHICLE DESIGN AND CHARACTERIZATION 
For intracellular gold nanoparticle formation, all of the constituents (sans chloroauric acid) are 
present in cellular systems. This intracellular gold nanoparticle formation has been demonstrated 
previously in mammalian cells, however, only through bulk diffusive treatments, treatments 
lasting more than 24 hours, and typically treatments are in solutions which contain no cell nutrients 
(such as DPBS).120–125 These treatment scenarios are non-ideal in terms of minimizing the impact 
on cellular health. To minimize the caustic properties of chloroauric acid we aim to deploy ionic 
gold salts in discrete nano-scaled clusters. If we are successful in deploying ionic gold in in discrete 
nanoscaled clusters, it could potentially allow us to reduce the overall dosage required for 
intracellular GNP formation, and in turn reduce impact on cellular physiology. For this ionic gold 
delivery vehicle to successfully enable intracellular reduction of ionic gold by action of cellular 
biomolecules, it is necessary that the delivery vehicle: a) will not spontaneously reduce ionic gold, 
b) will contain the ionic gold in discreet nanoscale packets c) will have the capacity to interact 
with the cells, and d) that cellular biomolecules will have access to the gold ions for nanoparticle 
formation. While chloroauric acid can be readily reduced by a large variety of functional groups, 
it is not readily reduced by ether groups, carbon-carbon single bonds nor under acidic pH 
conditions. With this knowledge in hand, hydroxyl terminated polyethylene glycol (Mn=10,000 
g/mol) (PEG) was used as  the ionic Au3+ delivery vehicle. The reasoning for this choice being 
that PEG is known to cluster with ionic gold in acidic pH solutions,95 and shouldn’t provide 
spontaneous GNP formation. We do not suspect that PEG would induce spontaneous GNP 
formation as polyol-based Au/Ag nanoparticle synthesis, where PEG could function as a reductant, 
typically require much higher temperatures (160°C) than utilized for cell culture (37 °C).126 In a 
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typical process forming the ionic gold delivery vehicle, HAuCl4 (14 µmol) and PEG (5 µmol), are 
co-clustered in a sealed glass vial with 2 ml of carbon filtered deionized water (pH=4). We 
observed that compared with neutral in acidic conditions (compared with neutral pH), PEG 
molecules formed clusters and positively charged gold ions were seen to preferentially localize 
within these clusters ( Figure 7A and B). This mixture of ionic gold and PEG was then incubated 
in a 37°C water bath for 30 minutes to ensure thermal equilibrium was achieved before being 
diluted for analysis or cell treatment. A UV-VIS electromagnetic spectra, lacking absorbance 
peaks characteristic of plasmon formation confirmed that the gold in these Au-PEG clusters was 
ionic and not reduced in nature (Figure 7C). This spectrum revealed a single absorbance maximum 
at 213 nm, which is typical of ionic gold, with no observable peak in the 500-700 nm range that is 
characteristic of the surface plasmonic resonance of reduced gold. Additionally, no visible color 
change or precipitant formation was observed if the solution was left undisturbed on the benchtop 
(RT) for 30 days (all treatments and samples used for analysis were made fresh). The discrete Au-
PEG clusters were 288 ± 46 nm in diameter, as quantified by transmission electron microscopy 
(TEM) (Figure 7B). From scanning electron microscopy-energy dispersive spectrum (SEM-EDS) 
we confirmed that the Au-PEG clusters contain gold (Figure 7D and E) and that the gold is 
contained solely within the PEG clusters, not simply dispersed within the solution. The dark 
contrast in TEM afforded by these clusters (Figure 7B), as well as light scatter from dark field 
hyperspectral imaging of the clusters in solution (Figure 7F and G) further supports these 
observations that the ionic gold is localized within the PEG clusters. The light scatter afforded 
through enhanced dark field hyperspectral imaging for the non-reduced ionic gold particles 
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confirmed the lack of surface plasmonic resonance peaks that would correspond with reduced gold. 
The light scattering peak at 420 nm is an artifact of the Vis-NIR liquid light guide which transmits 
light beginning at 420 nm. From these spectral and microscopic techniques, we have characterized 
our delivery vehicles as containing ionic gold in discrete nanoscaled packets (without auto-
reduction).  
 
Figure 7 Characterization of 
ionic Au-PEG delivery 
vehicle. Representative TEM 
images of PEG (A) and ionic 
Au-PEG clusters (B).   UV-
Vis absorbance spectrum of 
ionic Au-PEG clusters (200-
800 nm) (C). Electron 
dispersion spectrum (D) of 
ionic-Ai-PEG clusters 
captured from SEM-EDS of 
(E). Purple spectra 
corresponding to clusters 
signal and Blue spectra 
corresponding to background.   
Spectral intensity of light 
scatter (F) obtained through 
hyperspectral enhanced dark 
field imaging of discreet Au-
PEG clusters in solution with 
2x digital magnification 




   
In a typical process forming the ionic gold delivery vehicle, clusters of HAuCl4 (0.014 mmol) and 
PEG (0.050 mmol), mn=10,000 g/mol) are co-clustered in a sealed glass vial with 2 ml of carbon 
filtered deionized water (0.2 µm cellulosic membrane, pH=4). In acidic conditions, PEG molecules 
will cluster and positively charged gold ions will preferentially localize within the PEG clusters 
than within the acidic solution (Figure 8 and B). This mixture of ionic gold and PEG was then 
incubated in a 37°C water bath for 30 minutes to ensure thermal equilibrium is achieved before 
being diluted for analysis or cell treatment. To confirm that the gold in these Au-PEG clusters was 
ionic and not reduced, a UV-VIS electromagnetic spectra was recorded to determine plasmon 
formation or lack thereof (Figure 8C). This spectrum revealed a single absorbance maximum at 
213 nm, which is typical of ionic gold, with no observable peak in the 500-700 nm range that is 
characteristic of the surface plasmonic resonance of reduced gold. Additionally, no visible color 
change was observed if the solution was allowed to sit on the benchtop for 30 days (using only 
fresh Au-PEG clusters for all cellular applications). The discrete Au-PEG clusters were 288 ± 46 
nm in diameter, as quantified by transmission electron microscopy (TEM) (Figure 8B). From 
scanning electron microscopy-energy dispersive spectrum (SEM-EDS) (Figure 8D and E) we 
spectroscopically confirmed that the putative Au-PEG clusters do in fact contain gold and that the 
gold is contained solely within the PEG clusters, not simply dispersed within the solution. Dark 
TEM contrast afforded by these clusters (Figure 8B), as well as through dark field hyperspectral 
imaging of the clusters in solution (Figure 8F and G), supports these observations.  The light 
scatter afforded through transmitted enhanced dark field hyperspectral imaging for the non-
reduced ionic gold particles confirms the lack of surface plasmonic resonance peaks that would 
correspond with reduced gold. The light scattering peak at 420 nm is an artifact of the Vis-NIR 
liquid light guide which transmits light beginning at 420 nm.   
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Figure 8 Confirmation of in vitro reduction occurring en route. Spectral intensity of light scatter (A) obtained 
through hyperspectral enhanced dark field imaging of MCF-7 Cells treated with Au-PEG clusters (B). Scheme 
(C) with representative TEM images describing the reduction of ionic Au-PEG clusters (Ci), upon their interaction 




   
3.2.2 INTRO TO CONCEPT AND CAPACITY FOR IN VITRO REDUCTION 
Ionic Au-PEG clusters, applied at 233 nM Au3+, were capable of enabling a cellular reduction 
within four hours of treatment in human breast cancer cell cultures (MCF-7) in full cell media 
(containing 10% FBS, with 1x penicillin and streptomycin). Previous applications for generating 
gold nanoparticles intracellularly, typically apply 1 mM of ionic gold over time periods greater 
than 24 hours.120–125 When applied diffusively at lower concentrations (0.1 mM,123,124 0.25mM125) 
or at shorter time periods (12 hrs,125 15 hrs122), however, the amount of formed plasmonic gold 
nanoparticles were negligible or considerably reduced. From our application, we were able to 
confirm the transition of ionic to plasmonic gold through the spectral library obtained from 
enhanced dark field hyperspectral imaging of Au-PEG clusters reduced through interactions with 
MCF-7 cells (Figure 8A and B). To confirm that these plasmonic nanoparticles were internal and 
not simply on the cell surface, TEM imaging of MCF-7 cells treated with Au-PEG clusters was 
performed (Figure 8C). In the course of this reduction, there was an observable electron density 
focusing in formed particles as well as with a dark continuous irregularly shaped border along the 
periphery (Figure 8C). To confirm that gold nanoparticle formation is occurring en route to 
cellular internalization and not by undesired reactions with either the culture plate coating or the 
culture media, we undertook control experiments. With a high number of primary amines on the 
adherent culture plate surface (poly-L-lysine coating), a reduction of ionic gold within the solution 
of the culture plate could potentially occur. After incubating the ionic Au-PEG clusters for 24 
hours at 37°C on standard culture plates, no reductive or structural changes were observed (Figure 
9A). Bovine serum albumin (BSA), a protein nutrient source within our culture media, is capable 
of gold nanoparticle reduction with the aid of mild to strong reductants or through pH 
manipulation.85,127 We determined BSA not as the source of gold biomineralization in our system, 
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as the fresh culture media (containing BSA) was not able to reduce the ionic gold clusters (24h, 37 
°C) as confirmed through TEM images of this treatment solution (Figure 9B). For BSA based 
biomineralization procedures, it is necessary to include strong/mild reductants or basic pH 
manipulation.85,127 contrary to these, neither strong/mild reductants or basic pH manipulation are 
present within our system. To confirm that our gold nanoparticle formation is enhanced directly 
as result of our delivery vehicle we collected Raman cell mapped images of cells treated with our 
Au-PEG clusters, chloroauric acid (Au3+) (lacking PEG); and a negative control containing PEG 
and sodium salt (Na+) in equal molar concentration of the analyte (Au3+ or Na+). From this four-
hour treatment, Au-PEG were markedly enhanced (8x) compared to cells treated with Na-PEG or 
just chloroauric acid (Figure 10A and B). Additionally, this Au-PEG treatment begins to provide 
plasmonic enhancement as early as 30 min after treatment (Figure 10A). This enhancement can 
only arise from species within a range less than 100 nm. This plasmonic enhancement, only found 
with the Au-PEG treatment additionally confirmed the essential role of discretion of the Au3+ 
Figure 9 TEM images from extracted solution of ionic Au-PEG treatments to cell culture plates with a 
magnification of Au-PEG cluster (A), and fresh cell culture media incubated with Au-PEG clusters (B). 
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cations within a delivery vehicle for plasmonic nanoparticle formation at the applied 
concentrations and time frame.  
 
 
Figure 10 Raman spectra (A) of cells treated with either ionic Au-PEG clusters after 240 min (Burgundy), 120 
min (Red), 60 min (Orange), 30 min (Yellow), Au3+ (Green), or Na-PEG (Blue), with corresponding bright field, 
Raman mapping (of 2800-3000 peak intensity), and merged images  for 240 min treatments of  Au-PEG, Au3+, 
and Na-PEG(B). Scale bars for B are 20 µm. Raman spectra of cellular fractions obtained from MCF-7 cells 
treated with Au-PEG (C) including the nucleus and large organelles (Red); mitochondria, lysosomes, and other 
medium sized organelles (Green); membrane fragments (Blue); and highly soluble/cytosolic molecules (Violet); 
and the glass slide without cell fractions (Black). SDS-PAGE stained with Coomassie Blue with intensity plots 
overlaid (D) of protein from the nuclear fraction of MCF-7 cells without treatment (Green), treated with Na-PEG 
(Blue), or Au-PEG (Yellow) with standard SDS-PAGE conditions (lighter shaded colors, left three lanes), or 




   
3.2.3 BIOMOLECULE INVESTIGATION 
In order for this process, wherein GNPs are formed intracellular by action of cellular biomolecules, 
to be used directly for biomedical applications (whether they are diagnostic, therapeutic or both) 
knowledge of their formation process for and the affecting biomolecules must be obtained. To 
obtain this knowledge pertaining toward their formation process and affecting biomolecules would 
provide information to the pathological pathways which this process could be applied for 
diagnostic/therapeutic application. The enhanced Raman spectral maps afforded by the ionic Au-
PEG treatments (Figure 10A and B) also provided chemical information pertaining toward the 
biomolecules proximal to the intracellularly formed nanoparticles. These biomolecules, proximal 
to the intracellularly formed nanoparticles, may be biomolecules bound to or involved in their 
formation. These enhanced Raman spectra contain characteristic peaks arising from lipid (1175-
1385, 1446-1477, and 2849-2969 cm-1), and proteins (1590-1650 cm-1).128 Additionally, lack of 
presence of enhanced characteristic phosphate peaks at 2380-2450 cm-1 in the enhanced spectra 
allowed us to confirm that phosphates from the sodium phosphate buffer and/ or the nucleic acids 
are not participating in this gold reduction.128 However, the presence of amide, CH3 and CH2 peaks 
do not provide enough information on their own to be considered viable as a diagnostic tool nor 
does this information prove as sufficient to understand what processes are occurring within our 
system. To more precisely determine the biomolecules engaged in this intracellular reduction 
pathway and which portions of the cell they originate, cellular fractions were separated by density 
(through differential centrifugation) and the presence of plasmonic gold investigated through 
surface enhancement of Raman spectra (SERS) (Figure 10C). Mechanical lysis by tip sonication 
(30 s @ 1 Amp) of MCF-7 cells treated with the ionic Au-PEG, or untreated cells were used before 
separating by density into i) nuclei and large organelles, ii) mitochondria, lysosomes, peroxisomes, 
medium organelles, iii) cellular membrane fragments and iv) highly soluble peptides / cytosolic 
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molecules. For these cellular fractions, corresponding Raman spectra was collected from both cells 
treated and untreated with Au-PEG (Figure 10C and 11). An enhancement of the Raman spectra 
was observable for fractions containing nuclei membrane fragments from cells treated with Au-
PEG. Both of these fractions contained noticeable amide peaks at 1590-1650 cm-1.128 The presence 
of SERS in the nuclear and membrane fragment containing fractions indicates that at least two 
types of gold nanoparticles are being reduced that localize to these subcellular regions. From the 
prominent amide peak, we are led to believe that proteins could potentially be playing a significant 
role in this intracellular reduction process. This notion, that proteins are involved in cellular 
biomineralization has been explored by Singh et al.,125 however, their system is resultant from 
diffuse applications of Au3+ so we should not infer that these systems/processes are identical. To 
determine if proteins are involved in our intracellular gold nanoparticle formation, a Coomassie 
Blue stained, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used 
Figure 11 Raman spectra of cellular fractions (all from MCF-7 cells) of the nucleus and large organelles (Red); 
mitochondria, lysosomes, and other medium sized organelles (Green); membrane fragments (Blue); or highly 
soluble/cytosolic molecules (Violet). With Raman spectra of the glass slide (Black). 
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to separate proteins found in the fractions from cells treated with Au-PEG, Na-PEG, or untreated 
(Figure 10D and 12). We hypothesized that from our Au-PEG and Na-PEG treatments, protein 
band intensity may be affected; and from the Au-PEG treatment, nanoparticle-bound proteins 
could be slowed in their electrophoretic migration through the gel due to the additional mass of 
gold. From this gel, we found no discernable difference between specific bands present nor their 
relative expression between treatments (Figure 10D and 12). This information posed two possible 
major implications -- being that none of our treatments were affecting protein expression/integrity, 
that all proteins which were running through the gel in detectable quantities were not adhered to 
the gold nanoparticles, and/or that proteins were not involved in this process. Another possible 
explanation, however, was that one of the solutions used for preparing the protein for SDS-PAGE 
separation may possibly interfere and compete with the protein-gold interactions, effectively 
freeing the involved proteins from the nanoparticles. The primary candidate considered for this 
interference, possibly freeing the proteins, was β-mercaptoethanol (βME) as it is known to function 
as a highly efficient capping/ quenching agent for gold nanoparticle syntheses as well as being 
capable of breaking Au-S bonds between nanoparticles and protein.129 To determine whether βME 
was responsible for this freeing of Au-bound proteins we were prompted to run an additional gel 
comparing protein migration from the fractions of cells either treated with Au-PEG, Na-PEG, or 
no treatment in duplicate, but half would receive no βME (Figure 10D and 12). From observing 
these protein migrations comparing cellular treatments with and without βME, we found that 
several protein bands had lower intensities (almost complete lack of presence observable without 
aid) within the Au-PEG No βME treatment of the nuclear fraction while all other bands for the 
remaining treatments were identical (Figure 10D and 12). These identical protein band intensities 
indicate that neither our Na-PEG nor the Au-PEG treatment affected the protein 
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expression/integrity of proteins found within the nuclear fraction, while several proteins within 
that layer are attached to the formed plasmonic gold nanoparticles. Having observed protein 
impedance within the nuclear fraction of the ionic Au-PEG treated cells, we aimed to identify these 
proteins through LC-MS protein fingerprinting. To do this, we would remove proteins not 
Figure 12 SDS-PAGE stained with Coomassie Blue of cellular fractions including nuclear (A), medium organelle 
(B), membrane fragments (C), and cytosolic (D) regions of MCF-7 cells untreated, treated with Na-PEG, or Au-
PEG with either standard SDS-PAGE conditions [(+) βME], or without β-mercaptoethanol [(ᴓ) βME]. Arrows 
indicate direction of protein migration due to electrophoresis. 
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contributing to intracellular formation of plasmonic gold by running the nuclear fraction of ionic 
Au-PEG treated cells for an excess of time without βME then separate the top portion of the gel 
containing the wells from the bulk (Scheme 2).  
The proteins/ gold particles, located within either of these gel portions, were then extracted using 
a diffusion-mediated passive elution method.130–132 These extracted proteins were then briefly 
trypsinized to fragment the proteins present from extractions and centrifuged @ 6,000 x g to pellet 
any gold nanoparticles out of solution and then the supernatant containing soluble protein 
fragments was analyzed via LC-MS with MASCOT analysis (Matrixscience, Boston, MA) to 
identify the proteins represented by the protein fragments. Within the top portion of the gel which 
contained proteins which were impeded through the gel most, there were 2239 different protein 
fragments. These 2239 different protein fragments found in the top portion of the gel, including 
only those with a protein score greater than 21 (α<0.05), and uniquely found in the top of the gel 
(excluding proteins found in the bulk portion) accounted for 16 different proteins (Table 2 and 3).  
Scheme 2 describing the process for separating Au-bound proteins from non-bound through gel electrophoresis, 




   
Table 2 Proteins identified from the LC-MS analysis and the subcellular regions in which they are located, as 




   
 
 
Table 3 Proteins identified from the LC-MS analysis and the molecular processes in which they are involved, as 




   
 
 
Table 3 contd. Proteins identified from the LC-MS analysis and the molecular processes in which they are involved, 
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The subcellular regions in which these proteins are located, as annotated on UniProt.org through 
COMPARTMENTS,133 include subcellular regions ranging from extracellular to the nucleus 
(Table 2). These involved proteins enable or are involved in 287 identified molecular processes 
as identified through phylogenetic-based propagation of functional gene ontology (GO) 
annotations (Table 3).134 Of these molecular processes, the most conserved GO term processes are 
related to binding (Table 4).  Eleven of the sixteen identified proteins are involved in binding 
processes, eight in protein binding, five in metal/calcium/cationic binding, three in ATP/nucleic 
acid binding, two in antigen binding, two which directly bind with each other, and two which bind 
actin filament (Table 4). These eleven proteins involved in molecular binding, and the intracellular 
reduction of gold nanoparticles are characteristically located in regions ranging from extracellular 
to the nucleus.133 Since our extraction and isolation of these gold-bound proteins was from the 
nuclear fraction and many of these proteins are not typically located in the nucleus, this suggests 
that this intracellular reduction may occur sequentially within multiple regions of the cell, 
accumulating a protein corona (which may facilitate the nuclear migration) (Scheme 3).  This 
proposed migratory path with sequential reduction toward the nucleus initiates as the ionic gold 
delivery vehicle (Scheme 3Ө) interacts with secreted proteins (Scheme 3A). To simulate this 
primary reduction process, which occurs extracellularly, we admixed ionic Au-PEG clusters with 
spent cell media (media cells have been incubated with cells for ~24 hrs). Through TEM imaging 
we were able to find electron density focusing within the PEG clusters potentially indicating 
nanoparticle formation (Scheme 3A). This electron density focusing is not observed when ionic 
Au-PEG clusters are admixed with fresh cell media (Figure 10B), indicating that this electron 
density focusing is resultant of cellular biomolecule secretions. The proteins involved in this 
primary reduction include those, which are involved in antigen binding/ phagocytosis (IGLL5, 
 
45 
   
IGHA1), metabolic/ catalytic activity (ZG16B, AMY2B, GBE1), cation binding (AMY2B and 
GBE1), and steroid binding (SCGB1D2).134 Two of these proteins involved in primary reduction 
are also located in multiple cellular regions (GBE1 and IGHA1) posing as potential migration 
enablers to these other cellular regions.133 In addition, their localization to the extracellular region 
Table 4 Proteins adhered to intracellularly formed nanoparticles identified through LC-MS of the nuclear 
fraction of MCF-7 cells treated with ionic Au-PEG clusters, their localization throughout cellular regions, and 
molecular binding processes (shared by at least two of these proteins). Proteins which do not share a binding 




   
GBE1 and IGHA1 are also located within the cytoplasm and plasma membrane regions 
respectively.133 This potential for mitigating migration is especially probably for IGHA1 as this 
protein is both located in the plasma membrane and involved in receptor-mediated phagocytosis. 
These two proteins potentially act as enablers for migration of the ionic Au-PEG clusters from the 
primary to secondary reduction phase wherein the clusters interact with the plasma membrane 
Scheme 3 Scheme of progressive reduction process for the intracellular formation of gold nanoparticles via 




   
(Scheme 3B). Through cellular TEM images of our ionic gold PEG clusters as they interact with 
the protein-rich membrane (Scheme 3B), we are able to see additional electron density focusing 
compared with that found via interactions with cell secretions. This additional electron density 
focusing shows nanoparticles within the clusters as more polydisperse than from the primary 
reduction with the addition of a dark electron-dense border contiguous with the plasma membrane. 
Additionally, from enhanced Raman signals found in the membrane of whole cells (Figure 10A 
and B) and in membrane fractions (Figure 10C) we understand that plasmonic nanoparticles exist 
in the plasma membrane. This secondary reduction, catalyzed by the protein-rich membrane may 
be initiated by IGHA1 as it found extracellularly, within the plasma membrane, and involved in 
receptor-mediated endocytosis. As this endocytosis is initiated, the ionic Au-PEG cluster is 
proximal to the plasma membrane, this proximity subjects the clusters to higher concentration of 
cellular proteins/biomolecules, which are either secreted or located within the plasma membrane 
providing an environment more conducive to nanoparticle formation. The proteins involved in this 
secondary reduction within the plasma membrane are involved in cation binding (IGHA1, 
CDH23), antigen binding (IGHA1), kinase regulation/binding (SRCN1, ITGB1BP1), protein 
transport (ITGB1BP1), receptor clustering (ITGB1BP1), as well as endocytosis (IGHA1).134 In 
addition to IGHA1 being localized to multiple cellular regions (extracellular and plasma 
membrane), SRCN1 and ITGB1BP1 are also found in multiple cellular regions as potential 
migratory enablers. In addition to being located within the plasma membrane, SRCN1 and 
ITGB1BP1 are also both located within the cytoskeleton and ITGB1BP1 is additionally located 
within the nucleus.133 Once internalization of the ionic Au-PEG clusters is complete, we observe 
through TEM that the electron density at the center of these clusters diminishes (Scheme 3C). 
Additional to this hollowing of the Au-PEG clusters, the electron-dense border is less defined as 
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in the secondary reduction phase (during interaction with the plasma membrane). A possible 
explanation for this reduction in electron density is that passing through the plasma membrane 
could lower concentration of gold (ionic or reduced) remaining in the clusters, and that some 
portion of the gold remains within the plasma membrane after internalization. Evidence supporting 
this is found in the enhanced Raman spectra both in whole cells (Figure 10A and B) and the 
extracted cell fractions (Figure 10C) of those cells treated with ionic Au-PEG clusters showing 
enhanced Raman signal in the nucleus and membrane. This enhancement indicates that 
nanoparticles reside within the plasma membrane and the nucleus after the duration of our 
treatment (4 hrs). The notion that gold nanoparticles remain within the plasma membrane as the 
ionic Au-PEG clusters continue to migrate toward the nucleus is supported by the reduction of 
overall electron density observed as these clusters are fully internalized. After internalization 
through the plasma membrane, the direct path of the ionic Au-PEG clusters to the nucleus is not 
entirely clear as they undergo progressive reduction collecting proteins from the cytoskeleton 
(SRCN1, ITGB1BP1, CALM1), cytosol (PRDX4, GBE1), endoplasmic reticulum (PRDX4, 
JKAMP), and lysosome (GM2A) regions. The proteins in these non-nuclear regions are involved 
in metabolic processes (GM2A, CALM1), response to protein unfolding and oxidative stress 
(JKAMP, PRDX4), cation binding (CALM1, ITG1BP1), intracellular signal transduction 
(ITGB1BP1), and Titin binding (CALM1).134 The protein ITG1BP1, involved in intercellular 
signal transduction and cation binding, located within the plasma membrane, cytoskeleton, and 
nucleus;133 and CALM1, involved in cation binding and titin binding (a nuclear protein) pose as 
likely potential moderators for migration of ionic Au-PEG clusters to the nucleus for terminal 
reduction. If these two proteins (ITGB1BP1 and CALM1) retain their normal protein function 
wherein they transduce signals to the nucleus through binding, they pose as a potential route for 
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mediating the migration of the ionic Au-PEG clusters to the nucleus for terminal reduction or that 
proteins from the nucleus that interact with actin within the cytoskeleton may also cause this (TTN 
and FRG1).134 We ascertain that the ionic Au-PEG clusters migrate to the nucleus for terminal 
reduction because of the enhancement of the Raman (Mapping and fractions) combined with the 
identification of proteins bound to gold that are exclusively found in the nucleus (DDX31, FRG1, 
TTN). These proteins found exclusively within the nucleus are involved in cation/calmodulin 
binding (TTN), actin filament binding(TTN, FRG1), ATP binding (TTN, DDX31), and nucleotide 
binding (DDX31, FRG1, TTN). The protein titin, a molecular ‘control freak’ protein,135 with at 
least 23 cation-binding sites as well as binding calmodulin, poses as a potential gateway for the 
ionic Au-PEG clusters entry into the nucleus and then to the proximity of other nucleotide binding 
proteins (DDX31, FRG1).  This complete intracellular progressive reduction process, involving at 
least 16 different proteins localized throughout the cell (without apparent protein degradation 
Figure 10D and 12A-D), involving 287 molecular processes (including nucleotide binding), with 
terminal reduction within the nucleus poses as a particularly interesting and radically innovative 
theranostic application. This application, wherein nanoparticles are generated intracellularly 
through ionic Au-PEG clusters, would provide no plasmonic signal unless the treatment was 
successfully applied. Since diffuse ionic gold applied at these concentrations and time frames has 
been demonstrated as ineffective in generating plasmonic nanoparticles in observable quantities, 
signal would only occur from successful applications. When applied, gold nanoparticles generated 
intercellularly are bound to intact proteins involved in almost 300 molecular processes (including 
nucleotide binding), and the majority of these resulting nanoparticles localize within the nucleus. 
Photothermal therapy applied using this process would disrupt a host of molecular processes 
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simultaneously as well as directly cause heating of the nucleus, nuclear proteins, and potentially 
nucleotides directly. 
 
3.2.4 PEPTIDE AND AMINO ACID ANALYSIS 
To identify specific amino acids preferred in ionic gold reduction from these 16 proteins we would 
calculate the amino acid distribution in terms of overall percent for on-site protein fragments and 
off site protein fragments; compared against the amino acid distribution of the native protein 
BLAST data from Uniprot. To identify which amino acids in the identified proteins of interest, 
which were preferentially interacting with and reducing gold, we made an assumption that amino 
acids which participate actively/directly in reduction would be bonded to the gold nanoparticles 
and in turn underrepresented in the LC-MS fragmentation analysis compared with the native AA 
distribution (Figure 13). Comparing the distribution change in AA representation in on site 
proteins between fragment from LC-MS and whole native proteins (from uniprot), we were able 
to determine which AA’s were more highly represented in the identified protein fragments 
(unlikely for participation in gold reduction [Lys]; [Arg]; [Pro]), and which were represented in 
fewer instances than in the native protein (likely candidate AA’s [Leu]; [Thr]). These bound amino 
acids would not appear in as high frequency as the uninvolved AAs through LC-MS analysis due 
to the random nature of the fragmentation combined with the gravimetric separation of protein 
fragments from dense gold nanoparticles. However, this AA distribution change (Figure 13) does 
not account for the natural bias of the fragmentation process for LC-MS analysis. To account for 
the bias of the fragmentation process for LC-MS analysis we would subtract the change in AA 
representation identified between fragments and whole native proteins identified off site (bulk of 
the gel) (Figure 13). Amino acids, which have a positive change in AA representation between 
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fragments and whole native proteins identified off site are considered overrepresented ([Arg]) by 
the fragmentation process and those with a negative change underrepresented ([Cys]). To correct 
for the bias of the fragmentation process, we would subtract this bias/favorability in AA 
representation. Comparing the distribution change in AA representation in on site proteins after 
subtracting bias from the fragmentation process, we were able to determine more reasonably [Lys], 
[Arg], and [Pro] as unlikely candidates for reduction of gold and [Leu] and [Thr] as likely 
candidates (Figure 13). However, this AA distribution change with subtraction bias of the 
fragmentation process (Figure 13) does not account for the variability of AAs between on site and 
Figure 13 Changes in amino acid distributions from proteins identified through LC-MS; for on site proteins 
between those found in LC-MS fragments and in nature (RED); for off site proteins between those found in 
LC-MS fragments and in nature (Blue) representing the bias of the trypsin fragmentation and the LC-MS-
MASCOT system; for native proteins between those found on and off site (Yellow) representing the 
preference of the amino acid distribution between on and off site proteins; and various correction subtractions 
(Purple or Orange are partial corrections and black includes all corrections). 
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off site proteins (Figure 13). From comparing the AA distribution between on site and off site 
proteins in their native states, we identified AAs which more highly represented in the in target 
than off site proteins ([Pro]; [Val]; [Ser]; [Thr]) and AAs which which had lower representation 
([Leu]). After subtracting this bias of the AA distribution between native states of the on and off 
site proteins, we were able to identify [Lys], and [Arg] as overrepresented (likely not involved in 
reduction), and [Ser] and [Thr] as underrepresented (likely candidates for gold reduction).  
 
3.2.5 CELLULAR IMPACT IN VITRO 
To characterize the cytotoxicity of our ionic gold delivery platform we would compare apparent 
metabolic impacts (through MTT) and physical morphological changes (through flow cytometry 
without staining) against ionic gold (without PEG), PEG with ionic sodium, and Nifuroxazide with 
PEG (NIFU-PEG). From the MTT assay, our intracellular gold nanoparticle generating solution 
(Au-PEG) appears to reduce cell viability at lower treatment concentrations compared with Au3+ 
and Na-PEG with a treatment-response more concentration dependent than NIFU-PEG (Figure 
14A). However, there is an apparent inflection point in the apparent viability of Au-PEG treated 
cells which causes us to question reliability of this assay for our treatment. This inflection point 
occurs in MCF-7 cells as the apparent cell viability approaches 0%; and for MDAMB231 cells, 
this inflection point occurs without approaching 0% viability. We do not believe that this inflection 
point in apparent cell viability reflects an actual resurgence in cell viability or a change in treatment 
behavior at higher concentration, but actually reflects a reaction between unreacted treatments 




   
  
Figure 14 Cell viability of MCF-7 (A) cells as assessed via thiazolium blue (MTT) metabolic assay for cells 
treated with Na-PEG (Blue), Au3+ (Green), Au-PEG (Red), and Nifuroxazide mixed with PEG (Black). 
Titrated light interactions between ionic-PEG mixtures (same color scheme) as admixed with thiazolium blue 





   
To support this hypothesis, that the unreacted ionic gold can react with the Thiazolium Blue, we 
incubated our cell treatments (Au3+, Au-PEG, and Na-PEG) at titrated concentrations with 
Thiazoluim Blue (at MTT concentrations) and measure absorbance at the same wavelength used 
for the MTT assay (570 nm). From incubating our cell treatments with Thiazolium Blue in the 
absence of cells, we found a linear relationship between the concentration of ionic gold and the 
absorbance used to measure cell viability through MTT (Figure 14B). From this we can ascertain 
that the inflection point in the cell viability is due to unreacted ionic gold interacting with the 
Thiazolium Blue. In addition to this, if our treatment can potentially interact with dyes, dye based 
assays may not be ideal for characterizing impact. From this we would use stain-free flow 
cytometry (at IC50 concentrations as determined by MTT), comparing forward and side-scattered 
light, to observe how our treatment would potentially disrupt the distribution of cell size and 
complexity or if it would cause fragmentation/ or cell lysis to occur. To ascertain physical impacts 
of our treatment, we would plot flow cytometry results in a dot plot, comparing our treatment 
against negative (no treatment and Na-PEG) and positive controls (Au3+ and Nuf-PEG). From 
these treatments, we found a shift in forward-scatter and side-scatter toward lower intensities for 
all treatments in varying degrees compared with the no treatment (Figure 14C and D). The Nuf-
PEG resulted in the most dramatic population shift compared with the other treatments, then Na-
PEG and Au3+, followed by Au-PEG, indicating that Nuf-PEG had the largest impact, reducing 
size and complexity of the affected cells followed by Na-PEG and Au3+, followed by Au-PEG.  
We interpret this as indicating that our treatment of ionic gold PEG clusters as having less physical 





   
3.2.6 INVESTIGATION OF INTERNALIZATION MECHANISMS 
For potential theranostic applications, we would need to determine the internalization efficiency 
of our nanoparticles so we would be able to practically deliver high enough concentrations of gold 
for practical imaging (X-Ray, photoacoustic, or fluorescence), and/or therapeutic photothermal 
ablation. To calculate the internalization efficiency, we would treat MCF-7 cells in triplicate for 4 
hours with our ionic gold PEG clusters, collect the supernatant and cell pellet, submit both for ICP 
analysis for gold and use the total mass of gold in the cell pellet vs the supernatant to calculate the 
total internalized based on the treatment concentration. We found that nearly 50% of the gold was 
internalized for both breast cancer cell lines (Figure 15). We then investigated which 
internalization pathways were involved using a series of inhibitors that would selectively block 
major endocytosis pathways (Figure 15). Small molecule inhibitors for our study selected in such 
a way that they did not exert any considerable toxicity by themselves in the short period of 
incubation. Furthermore, they were chosen so that they do not affect the actin cytoskeleton post 
treatment.107,136 The working hypothesis of this study was based on the fact that a particular 
inhibitor would block a specific endocytic pathway and consequently not allow the nanoparticles 
to internalize in the cells via that particular pathway. A mixture of sodium azide (NaN3) and 2-
Figure 15 Percentage of gold internalizatio 
by MCF-7 cells via application of ionic Au-
PEG clusters at 0.24 mM Au3+(control), or 
ionic Au-PEG clusters with endocytosis 
inhibitors. Selected endocytosis inhibitors 
used were sodium azide and 2-deoxyglucose 
(NaN3), Nyastatin (Nys), chlorpromazine 




   
deoxyglucose (DOG), were used to inhibit glycogenosis and cellular respiration respectively, via 
energy dependent uptake.137 Chlorpromazine (CPM), was used to probe into the clathrin dependant 
entry, as it is known to reduce the formation of clathrin-coated pits due to reversible translocation 
of clathrin and its adapter proteins from plasma membrane to intracellular vesicles.138 Dynasore 
has been used to understand the inhibition of dynamin (GTPase) dependency in endocytosis of 
cells.139 Finally, nystatin, a sterol-binding agent, dissembles caveolae and cholesterol in the 
membrane, has been employed to study clathrin-independent inhibition of endocytosis.140,141 We 
would repeat our ICP analysis of internalized gold with these four inhibitors of various major 
pathways of cellular internalization. If the addition of any of these internalization inhibitors were 
to reduce the percent of treated gold found in the cellular pellet we would interpret this as a 
pathway which our endocytosis was routed. From this study, however, we found that none of these 
inhibitory treatments were able to reduce the internalization of the gold (Figure 15). We found the 
lack of impact on internalization by these inhibitors perplexing, as these pathways were involved 
in the majority of cellular internalization and approximately half of the gold was being internalized.  
 
3.2.7 THERANOSTIC APPLICATIONS IN VIVO 
From our application of ionic gold clustered with PEG, we have developed a unique system 
wherein gold nanoparticles are reduced by cellular biomolecules in a manner where the affecting 
biomolecules may retain functionality, including the capacity to guide the remaining cluster to the 
nucleus. The formation and migration of these gold nanoparticles to the nucleus presents high 
potential for theranostic photothermal ablative application as they result in nuclear delivery. To 
inquire to the theranostic potential for the intracellular generation of functional gold nanoparticles 
we would apply our ionic Au-PEG clusters to MCF-7 xenografts in J/NU mice comparing with 
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control injections of ionic Na-PEG. Intratumoral injections of ionic Au-PEG clusters presented 
fluorescence contrast via IVIS imaging with excitation wavelength of 430 nm and emission 
wavelength of 840 nm. This observed fluorescence emission is not uncommon for ultrasmall gold 
nanoclusters (<5 nm), wherein the emission wavelength can be tuned from 385 to 866 nm.142 From 
our system, wherein gold nanoparticles were generated intratumorally, fluorescence contrast was 
observable above background as early as one day after injection of ionic Au-PEG clusters; with 
increasing contrast between injection site and off site (or control injection sites) for up to two days, 
which would dissipate after a week (Figure 17A-E). This increase in fluorescence contrast 
between injection site and off-site local, suggests that nanoparticles may be continually forming at 
the injection bolus, intracellularly for up to two days beyond the injection time point. This 
fluorescence contrast between injection site and off site (no treatment) was not observed for ionic 
Na-PEG injections, which had no significant fluorescence contrast (all time scales observed). To 
investigate therapeutic potential, tumors injected with either Au-PEG or Na-PEG would receive 
laser treatments using 500 mW 633 nm continuous wave laser for 5 min (+ laser) or 0 min (- laser) 
periods with an ipad mounted IR camera (FLIR technologies) to monitor and quantify the 
temperature changes. When applications of laser ablation were applied, tumor temperatures would 
raise to 51.2 ± 1.7 ºC for successful Au-PEG treatments and 40.8 ± 1.0 ºC for Na-PEG treatments 
(Figure 17F-H). Successful hyperthermia is commonly defined as heating tissue to a temperature 
in the range <45°C for several minutes (5-10 min).143,144 Lesions/ scabbing and tumor remediation 
occured for tumors with successful applications of Au-PEG with two or fewer laser applications 
in all but one mouse (n=5). Laser applications made to successful Au-PEG treatments would 
reduce the apparent fluorescence contrast compared against no laser treatments (Figure 17A).  
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Figure 16 (A) Fluorescence 
contrast afforded via IVIS 
imaging (430Ex 840Em) between 
on-site and off-site across a one 
week period for treatments of 
Au-PEG with no photothermal 
treatment (Yellow), Au-PEG 
with photothermal treatment 
(Red), or Na-PEG (Blue).  Bright 
field (B and D) and fluorescence 
images (C and E) representitive 
of Au-PEG (B and C) or Na-PEG 
(D and E) treated mice (three 
days post injection) with arrows 
indicating intratumoral injection 
sites for either Na-PEG (Blue) or 
Au-PEG (Red). Temperature 
maximums averaged across laser 
treatments (F) as determined 
through FLIR IR thermal 
imaging with representitive 
thermal image of laser treatments 
made to mice with  Au-PEG (G) 
or Na-PEG (H) injections. Bright 
field, Raman spectral mapped 
and merged images of excised 
tumor treated with Au-PEG(± 
laser ablation)  or Na-PEG (± 
laser ablation) with 
corresponding Raman point 
spectra for positions designated 





   
This apparent reduction in fluorescence contrast from laser treatment is likely owed to this 
resultant hyperthermic process, either through loosening cell membranes and destroying tissue 
allowing nanoparticle escape and/or through the addition of thermal energy modifying the reaction 
kinetics (forming non-fluorescent nanoparticles). Hyperthermia causes cell damage by loosening 
cell membranes and denaturing proteins,145,146 and hyperthermic laser applications have been 
demonstrated to spontaneously reduce nanoparticles dependent on the laser heating.147–149 It is 
likely that a combination of these effects are taking place, wherein photothermal applications are 
simultaneously loosening tissue for the escape of fluorescent gold nanoparticles and unreacted 
ionic gold as well as forming hyperthermic laser induced gold nanoparticle formation (Scheme 4). 
Scheme 4 Artistic representation of how applications of ionic Au-PEG clusters will induce nanoparticle formation on 




   
Unsuccessful applications of Au-PEG (such as where the injection bolus was placed intradermal 
instead of intratumoral), would result in diffusive fluorescence with contrast between tumor and 
off-site no greater than Na-PEG (Figure 17A-C).  When applications of laser ablation were applied 
to unsuccessful injections of Au-PEG (with diffuse fluorescence and no effective contrast), tumor 
temperatures would raise to 40.7 ± 2.3 ºC, (no significant difference than Na-PEG). Unsuccessful 
injections of Au-PEG provided us with near immediate feedback and utility for our theranostic 
intracellular generation of gold nanoparticles. After initial failed injections, we would be able to 
receive fluorescent imaging confirmation pertaining toward the success of our application, 
allowing us to determine if we should attempt photothermal laser application or if we should rather 
wait for fluorescence to reduce to background (by waiting one week) before attempting a second 
injection attempt. If we applied laser therapy to unsuccessful injections, we would observe no 
hyperthermia impact (on or off site). To further investigate the ionic Au-PEG cluster for 
theranostic applications focusing on the intratumoral generation of gold nanoparticles, organs 
(tumors, sentinel lymph nodes, liver, kidneys, and spleen) were harvested and imaged either with 
Raman mapping or stained by H&E for bright field imaging. From Raman mapping, we found 
Raman enhancement in tumors treated with Au-PEG which had received photothermal ablation 
compared with the other treatments (Figure 16I). This supports the notion that photothermal 
ablation may induce nanoparticle formation which is separate from the cellular reduction. The 
application of ionic Au-PEG clusters to generate fluorescent and photothermally active 
nanoparticles intracellularly resulted in no pathological effects observable through our short-term 
experiment regardless of the success of the application. Additionally we demonstrated that 




   
  
Figure 17 (A) Fluorescence contrast afforded via IVIS imaging (430Ex 840Em) between on-site and off-site 
across a one week period for treatments of Au-PEG with no photothermal treatment with intratumoral 
injections (Yellow), Au-PEG with intradermal/bad injections (Orange), or Na-PEG (Blue).  Bright field (B) 
and fluorescence images (C) representitive of mice with Au-PEG with intradermal/bad injection (three days 
post injection) with arrows indicating intratumoral injection sites for either Na-PEG (Blue) or Au-PEG (Red). 
Temperature maximums averaged across laser treatments (D) as determined through FLIR IR thermal imaging 
with representitive thermal image of laser treatments made to mice with  Au-PEG with intradermal/bad 




   
3.3 GENERATING PERSONALIZED NANOTHERANOSTICS WITH ENDOGENOUS 
BIOMATERIALS 
Some of the most advanced of these strategies for targeting and functionalizing nanoparticles 
utilize whole cellular membrane as a holistic approach for evading immune response  with 
combined targeting.65,66,74,150 This strategy, wherein whole cell membrane is utilized for 
functionalization takes advantage of the complexity of the protein-lipid content and organization 
which cells normally use for communication and interaction (instilling these capacities to 
nanoparticle vectors). Many approaches for functionalizing the surface of nanoparticles rely on 
multi-step processes, which necessitate the addition and then removal of synthetic molecules, 
heating, and pH modifications. Processes that rely on heating, and basic pH conditions can have 
deleterious, modifying effects on the capping biomolecules, potentially disabling or reducing their 
innate capabilities.151–156  Additional to this issue of capping agent destruction and modification, 
each step which requires addition or removal of excess reaction constituents or side products will 
result in loss of product. In order to streamline the monetization and clinical translation of 
nanotherapeutics, special consideration must be attributed toward the cost associated with pre and 
post processing, as well as toward biocompatibility of both the waste and goal products. The 
incorporation of ‘green chemistry’ principles, wherein natural biocompatible products are utilized 
in the production process, greatly reduces workload and environmental impact because they 
require fewer synthetic and purification processes.  Here, we describe methods for forming 
functionalized gold nanoparticles at room temperature in a single step using nicotinamide adenine 
dinucleotide (NADH). Our single-step process for forming functionalized gold nanoparticles at 
room temperature, without pH modification, or synthetic molecules enables formation of 
nanoparticles which can either be functionalized by individual proteins (demonstrated with FBS) 
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or whole cells membrane (extracted B16-F10 cell membrane). The products of our single-step 
synthesis have been optimized to maintain biomolecule integrity and so that there are no 
purification steps required. To characterize our nanoparticles in terms of their shape, size, surface 
functionality, and biomolecule integrity we employed light-based spectroscopy techniques, 
molecular modeling, electron microscopy, light scattering, and gel electrophoresis techniques. In 
order to compare our optimized biomolecule-functionalized nanoparticles against current 
standards (which require synthetic linkers, heating, or pH manipulation), we employed metabolic 
and live/dead assays as well as light-based microscopy/spectroscopy in vitro while comparing 
biodistribution, immune, and pathological effects in vivo. 
 
3.3.1 INITIAL INVESTIGATION AND INSPIRATION FOR SINGLE-STEP SYNTHESIS 
To improve upon any synthetic process where improvements must be made to pre-processing, 
processing, and post-processing to minimize costs (either direct or associative), and maximize the 
end production. Because of this notion, single-step processes which require minimal inputs are 
ideal if they are able to produce adequate products and especially so if superior products can be 
made this way. Knowing this, our first approach to develop cell membrane coated gold 
nanoparticles utilized a minimalistic approach; admixing membrane fragments with with 
chloroauric acid (HAuCl4), potentially forming gold nanoparticles either coated or embedded in 
collected cell membrane. From this simplistic mixture we found plasmon formation through both 
enhanced Raman as well as UV-Vis spectra  (Figure 18A and B). The enhanced Raman spectra 
of the membrane fraction admixed with ionic gold (Au3+) has near identical spectral profile to the 
membrane alone with shifting and enhancement of those peaks indicating that membrane 
molecules are present and near a plasmonic surface. Within the UV-Vis spectra, plasmon 
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formation is only visible through extreme magnification indicating that very few plasmonic gold 
nanoparticles were actually formed. Additionally to this, plasmon formation observable through 
either enhanced Raman or UV-Vis will only occur through the use of freshly collected cellular 
membrane (<3 hours from mechanical cell lysis). Through transmission electron micrographs 
Figure 18 UV-Vis spectra (200-750 nm) with magnification (450 – 650 nm) of B16-F10 cell membrane fraction 
(solid line) and the same components with the addition of 0.214 mM Au3+ (dashed line) (A). Raman spectra (1000-
3000 cm-1) of B16-F10 cell membrane fraction (solid line) and the same components with the addition of 0.214 mM 
Au3+ (dashed line) (B). Raman excitation laser used is 532 nm. TEM image of B16-F10 cell membrane fraction 
admixed with 0.214 mM Au3+ (scale bar is 100 nm) (C). Coomassie Blue Stained SDS-PAGE of B16-F10 cell 
membrane fraction (left to right) without additional components, with low pH control (<4), 0.214 mM Au3+, and a 




   
(TEMs) we are able to see that there is no detectable uniformity of structure to the ´nanoparticles´ 
as they appear heterogenous in shape, size and likely the membrane molecules involved in surface 
coating as well (Figure 18C). We believe that not only the size, and shape, but also the surface 
coating of these nanoparticles may also be heterogeneous because the gold nanoparticle pre-cursor 
material (HauCl4) provides an acidic environment wherein large components of these membrane 
molecules (namely proteins) can be degraded (through acid hydrolysis).154–156 To investigate the 
integrity of the membrane molecule surface integrity, namely the protein content, we used 
Coomassie Blue staining of an SDS-PAGE of membrane whole membrane either untreated, pH 4 
treated, or Au3+ treated (Figure 18D).  From this, we found total fragmentation of proteins within 
our Au3+ treated cell membrane, and near total fragmentation in the pH 4 treatment. From this 
information gathered through Coomassie stained SDS-PAGE, TEM, UV-Vis, and Raman analysis 
we learned that simple two component admixation of fragmented cellular membrane and ionic 
gold is inadequate for the purpose of forming nanoparticles suitable for biomedical application, 
however, there is potential that this conceptual procedure can be optimized further. From the 
information provided through through Coomassie stained  SDS-PAGE, TEM, UV-Vis, and Raman 
analysis pertaining toward the inadequacies of this synthesis we saw opprotunity to optimize the 
reaction in terms of: (1) optimization of pre-cursory gold (Au3+) concentration, reductant 
concentration (2) (unknown component within membrane fraction which degrades over time),  (3) 
capping molecule density (membrane molecules), and (4) The reaction environment in terms of 
environmental pH. We identified NADH as an endogenous reductant which we were able to use 
to optimize a single-step-synthesis of plasmonic gold nanoparticles composed entirely of cellular 
membrane and plasmonic gold without require heating, pH modification, or synthetic molecules 
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enabling biomedical application of these nanoparticles immediately upon completion of synthesis. 
 
3.3.2 SELECTION AND INVESTIGATION OF NICOTINAMIDE ADENINE 
DINUCLEOTIDE AS A POTENTIAL ENDOGENOUS REDUCTANT 
Nicotinamide adenine dinucleotide (NAD), in it’s oxidized (NAD+) and reduced (NADH) state, 
are ubiquitous molecules in all cellular organisms as reducing agents, coenzymes, and energy 
sources. For its cellular reductive capabilities, we hypothesized that NADH may be able to 
function as a reducing agent to form gold nanoparticles and that NAD+ would have no, or 
significantly lower nanoparticle forming capacity. We predicted that the active site for NADH 
utilized in metabolic cellular reductive processes would act on ionic gold to form nanoparticles. 
To test this theory, equimolar concentrations of NADH and Au3+ were admixed.  Immediately 
after mixing a color change from the yellow ionic-gold to dark red was observed, indicating 
nanoparticle formation. This mixing was repeated with NAD+ but no color change was observed. 
From UV-Vis spectra collected of these two mixtures of either NADH or NAD+ with ionic gold 
an observable plasmonic peak was found only in the mixture where NADH was added, indicating 
that that nanoparticles were only formed through the addition of NADH (Figure 19A). Dynamic 
light scattering (DLS) measurements of the nanoparticles revealed a hydrodynamic diameter of 
13±3 nm. Transmission electron microscopy (TEM) images of the formed nanoparticles revealed 
dry diameters of 7±3 nm (Figure 19B). Fourier transform infrared (FTIR) spectra collected of 
these mixtures, as well as separate constituents, revealed the chemical conversion of NADH  
NAD+ upon interactions with Au3+(Figure 19C and D). This chemical conversion was confirmed 
through a calculated 99% correlation between FTIR spectra of ionic gold mixed with NADH and 
NAD+ alone (Figure 19D). These spectra contain several peaks unique to only the NADH spectra 
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within the 3000-3500 region as well as within the fingerprint region, while remaining spectra (from 
NAD+, Au-NAD+, and Au-NADH) contain identical spectra with ≥97% correlation with each 
other. To accurately analyze the charge distribution of a molecule, electrostatic potential energy 
values at different locations must be calculated. To portray this data in an efficient manner, an 
electrostatic potential map could be used to represent it visually. To make the electrostatic potential 
Figure 19 UV-Vis spectra (200-750 nm) of NADH (Blue), NAD+ (Red), Au3+ (Green), Au3+ mixed with NADH 
(Purple), or Au3+ mixed with NAD+ (Orange) (A). TEM image of NADH admixed with Au3+ (scale bar is 50 nm) 
(B). FTIR spectra (1800 - 4000 cm-1) of NADH (Blue), NAD+ (Red), Au3+ mixed with NADH (Purple), or Au3+ 
mixed with NAD+ (Orange) (C). Correlation (%) of FTIR spectra (D). Electrostatic potential mapping of 
hypothesized reduction pathway by NADH which does not occur via NAD+ (E). 
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energy data easy to interpret, a color spectrum, with red as the lowest electrostatic potential energy 
value and blue as the highest, is employed to convey the varying intensities of the electrostatic 
potential energy values. In Figure 19E, we notice from the electrostatic potential structure of 
NADH that it has low potential energy (red) and hence it can reduce to NAD-Au on interactions 
with Au3+, thereby reaching a higher electrostatic potential energy (blue-red surface). However, 
since NAD+ already has high electrostatic potential energy (blue-red surface), it does not interact 
with Au3+ ions.  
 
3.3.3 NADH-AU CONCENTRATION EFFECTS 
After the initial findings, indicating that ionic gold is capable of being reduced by NADH, we 
aimed to determine the effective concentrations at which this synthesis can occur. While 
maintaining the molar ratio of NADH:Au3+ at 1:1 we titrated the concentration of these reactants 
from 17.60 to 0.36 mM. Apart from the lowest concentration of 0.36 mM, we found no changes 
in plasmonic peak absorbance relative to the A340 peak from NADH nor any changes in plasmonic 
peak wavelength, from UV-Vis measurements of the titrated solutions (Figure 20A and B). This 
stability of the plasmonic peak across concentrations of reactants used indicates that within our 
tested concentration ranges our reaction can be successfully scaled without impacting the 
nanoparticle size or shape (Figure 20C). This notion that the nanoparticle size and morphology 
remains similar across concentrations is further supported by DLS measurements of the 





   
3.3.4 NADH-AU RATIO TITRATIONS 
After determining a workable range of concentrations for gold nanoparticle synthesis we then 
aimed to optimize the ratio of reactants, first titrating NADH against Au3+, then titrating Au3+ 
against NADH. When titrating the amount of Au3+ while keeping NADH constant we observed 
the ratio of formed nanoparticles to unreacted NADH by comparing the ratio of the absorbance 
at 550 nm (plasmonic peak) to the absorbance at 340 nm (NADH absorbance peak). The 
A550/A340 ratio continued to increase as we increased the amount of Au3+ until we approached 
a ratio of 2.5:1 (NADH: Au3+) (Figure 21A and B).  From these syntheses, we observed no 
significant change in hydrodynamic diameter (Figure 21C). When titrating the amount of 
NADH while keeping Au3+ constant we observed a different trend; one wherein the A550/A340 
ratio increased until a 1:1 ratio of Au3+ : NADH occurred, and then plateaued until a 4:1 ratio. 
These spectral changes were also reflected through DLS measurements of the hydrodynamic 
diameters with a similar trend. This atypical relationship between Au3+ concentration and 
plasmon could be due to the pH influence of Au3+, or due to the catalytic oxidation of NADH by 
gold nanoparticles.157,158 
 
Figure 20 UV-Vis spectra (200-750 nm) of Au3+ mixed with NADH at equimolar concentrations (mM) (A). Ratio 
of absorbance at 550 nm to absorbance at 340 nm for mixtures of Au3+ and NADH at equimolar concentrations 




   
3.3.5 NADH-AU PH EFFECTS 
After the initial findings, indicating that ionic gold is capable of being reduced by NADH, we 
aimed to determine the effective concentrations at which this synthesis can occur. While 
maintaining the molar ratio of NADH:Au3+ at 1:1 we titrated the concentration of these reactants 
from 17.60 to 0.36 mM. Apart from the lowest concentration of 0.36 mM, we found no changes 
in plasmonic peak absorbance relative to the A340 peak from NADH nor any changes in plasmonic 
peak wavelength, from UV-Vis measurements of the titrated solutions (Figure 22A-D). This 
stability of the plasmonic peak across concentrations of reactants used indicates that within our 
tested concentration ranges our reaction can be successfully scaled without impacting the 
nanoparticle size or shape. This notion that the nanoparticle size and morphology remains similar 
across concentrations is further supported by DLS measurements of the hydrodynamic diameter 
as well as through TEM (Figure 22F-I).  
 
3.3.6 PRE-OPTIMIZATION OF SYNTHESIS WITH FBS PROTEIN 
To realize an NADH driven synthesis of gold nanoparticles capped by whole membrane we first 
aimed to characterize a similar but simpler process with a single homogenous protein as cap. 
Figure 21 UV-Vis spectra (200-750 nm) of Au3+ mixed with NADH at titrated mole ratios between 0:1 – 4:1 (Au3+ 
: NADH). Ratio of absorbance at 550 nm to absorbance at 340 nm for mixtures of Au3+ and NADH at equimolar 





   
Where whole cell-membrane contains a complex protein and biomolecule content, we aimed to 
first characterize and optimize our single step synthesis of gold nanoparticles driven by NADH 
capped by a single protein-component as (1) a proof of concept for whole membrane, (2) a means 
of pre-optimization with a more readily available component, and (3) use other methods developed 
for single protein as a means of comparison. We chose to use fetal bovine serum protein as a model 
system of single step gold reduction with attached protein, as FBS is readily available and the 
literature of FBS bound gold nanoparticles is established for single-step-synthesis methods for 
Figure 22 UV-Vis spectra (200-750 nm) of NADH at titrated pH ranging from 7.1 - 3.3 (A). Ratio of absorbance at 
340 nm to absorbance at 280 nm for NADH at titrated pH ranging from 7.1 - 3.3 (B). UV-Vis spectra (200-750 nm) 
of Au3+ mixed with NADH (1:1 mole ratio) at titrated pH ranging from 7.1 - 3.3 (C). Ratio of absorbance at 550 nm 
to absorbance at 340 nm for mixtures of Au3+ and NADH (1:1 mole ratio) at titrated pH ranging from 7.1 - 3.3 (D). 
Hydrodynamic diameter for mixtures of Au3+ and NADH (1:1 mole ratio) at titrated pH ranging from 7.1 - 3.3 (D). 
TEM Images for mixtures of Au3+ and NADH (1:1 mole ratio) at titrated pH of 6.0 (F), 5.7 (G), 5.4 (H), and 5.1 (I). 




   
preparing these nanoparticles which involve heating, pH modification and/or synthetic 
molecules.85,127,159,160 With the presence of FBS in a reduction synthesis of gold nanoparticles via 
NADH, the plasmonic absorption relative to synthesis without FBS is considerably lowered by 
UV-Vis intensity (Figure 23A and B and Figure 24A). From DLS measurements (Figure 23C), 
we observed ~10X increase in apparent hydrodynamic diameter. However, this apparent 
hydrodynamic diameter may be representative of FBS protein aggregation, accumulation, etc… as 
this large hydrodynamic diameter (~200 nm) can also be observed through the admixing of NADH 
and FBS without any gold components (Figure 24B). Through TEM (Figure 24C-I) it becomes 
apparent that the actual gold nanoparticles are considerably smaller than the measurements 
obtained through DLS, and that, in fact, the gold nanoparticles become larger and more 
polydisperse as concentrations of FBS are increased (contrary to DLS measurements). Although 
plasmonic absorption may have been reduced, the Raman intensity enhancement from these 
particles is enhanced (10x maximally) (Figures 23D-F). This conflict between UV-Vis and Raman 
indicated to us that gold nanoparticles may be reduced in quantities similarly to those without FBS, 
however, the FBS may be occluding the light absorption by the particles as it may be coating them. 
To investigate the FBS/ protein integrity after this synthesis we would use Coomassie Blue stained 
SDS-PAGE with our NADH driven synthesis (Figure 23G). From this gel we were able to find 
more intact FBS protein through an observable and quantifiable FBS band intensity compared with 




   
Figure 23 UV-Vis spectra (200-750 nm) with magnification (550 – 650 nm) (A), Relative plasmon formation (B), 
Hydrodynamic diameter (C), Raman Spectra (D), Raman intensity maxima (E), and Raman maxima location (F) of 
Au3+ mixed with NADH (at 1:1 mole ratio) with titrated concentrations of FBS (0.00-2.60 mg/ml). Relative plasmon 
formation interpreted as the absorbance at 550 nm relative to the absorbance at 280 or 340 nm (reflective of residual 
NAD+ or NADH respectively) normalized to the ratio without FBS. Coomassie Blue stained SDS-PAGE with βME 
present (G), or lacking βME (H) of Au3+ mixed with NADH (at 1:1 mole ratio) with titrated concentrations of FBS 






   
This SDS-PAGE does not inform us, however, if these FBS proteins are bound to the resultant 
gold nanoparticles. We can infer that they are closely localized through the enhanced amide peak 
within the Raman spectra (Figure 23D), and through TEM micrographs (Figure 24C-I), but we 
cannot make any statement toward the quality of this adhesion if there exists any at all. To discover 
whether the FBS protein is bound or simply localized to the formed gold nanoparticles we would 
utilize a modified SDS-PAGE without the use of the strong reducing agent β-mercaptoethanol (β-
Me). For SDS-PAGE, β-Me is primarily utilized to reduce di-sulfide linkages between proteins, 
Figure 24 UV-Vis spectra (200-750 nm) (A), and hydrodynamic diameter (B) of Au3+ mixed with NADH or FBS, 
or FBS mixed with NADH (NADH : Au3+ is 1:1 and FBS is at 0.78 mg/ml). TEM images of Au3+ mixed with 
NADH (at 1:1 mole ratio) with 0.52 (C), 0.78 (D), 1.04 (E), 1.30 (F), 1.56 (G), 2.08 (H), or 2.60 mg/ml FBS (I). 






   
but this reductive molecule can also form as a capping agent for gold nanoparticles, or as a 
replacing capping agent.129 For these previously stated reasons we believe that our unmodified 
SDS-PAGE displayed total protein content, and through action of β-Me, all proteins bound to the 
gold nanoparticles were ‘freed’ to run through the gel. To test this hypothesis, we ran a modified 
SDS-PAGE without β-Me (Figure 23H) so that we could observe protein content which is 
unbound to our nanoparticle system. We observed that the smallest proteins migrated an 
approximate equidistance in both β-Me positive and negative gels implying that these small 
Figure 25 Coomassie Blue stained SDS-PAGE (A) with βME present (+), or lacking βME (ᴓ) of NADH mixed with 
Au3+, FBS mixed with Au3+, NADH mixed with FBS, or protein ladder (from left to right for both gels). Plots of 
the gel image intensities as a function of distance for NADH mixed with Au3+ (B), FBS mixed with Au3+ (C), or 






   
proteins were unbound to the gold nanoparticles. The major FBS band, however, is completely 
gone in the β-Me negative gel. We are able to infer that this means that the main FBS protein band 
is adhered to the gold nanoparticles because when running FBS + NADH through β-Me positive 
and negative SDS-PAGE (Figure 25A-D) we are only able to observe minor changes in migration 
distance. Additionally from the β-Me negative gel, we were able to observe nanoparticle migration 
through the gel. We were able to ascertain that the slowest moving bands in the gel were, in fact, 
gold nanoparticles due to their red color before staining (not pictured), and the contents of lane 2 
(nearest to the ladder) contains no protein. Nanoparticle migration (i.e. size), are similar for all 
concentrations of FBS applied excluding the highest concentration of FBS (2.60 mg/mL) wherein 
nanoparticles become large and no longer migrate through the gel. For both β-Me positive and 
negative SDS-PAGE we do observe protein streaking (albeit less than FBS + Au3+ alone) (Figure 
25A and C). This streaking represents non-specific protein hydrolytic cleavage likely caused by 
the acidic environment provided by chloroauric acid. To mitigate this hydrolytic cleavage of the 
FBS protein we investigated if the synthesis could be produced in solutions buffered with sodium 
bicarbonate, and how different concentrations of sodium bicarbonate would influence this 
synthesis until achieving concentrations used for cell culture/ used by living systems.  
 
3.3.7 PRE-OPTIMIZATION OF SYNTHESIS WITH IN BUFFERED SOLUTION 
Using our simple synthetic method without FBS protein we used titrated concentrations of sodium 
bicarbonate from 0.00 to 1.5 mg/mL in order to observe changes in plasmon/ nanoparticle 
formation as resultant of the addition of buffer. From the addition of buffer we observed a near 
linear decrease in plasmon formation, as observed through UV-Vis spectra (Figures  26A and B). 
For all of these titrated buffer concentrations, we observed no change in hydrodynamic diameter, 
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indicating that the addition of buffer is only impacting the concentration of the resultant 
nanoparticles and not impacting the morphology (Figure 26C). At buffer concentrations 
equivalent to those found in common cell culture (1.5 mg/mL) we observed a decrease in plasmon 
Figure 26 UV-Vis spectra (200-750 nm) with magnification (550 – 650 nm) (A), Relative plasmon formation (B), 
and Hydrodynamic diameter (C), of Au3+ mixed with NADH (at 1:1 mole ratio) and titrated concentrations of sodium 
bicarbonate buffer (0.00-1.50 mg/ml). Relative plasmon formation interpreted as the absorbance at 550 nm relative 
to the absorbance at 280 (reflective of residual NAD+) normalized to the ratio without buffer. Raman Spectra (D), 
Raman intensity maxima (E), and Raman peak ratios (F) of Au3+ mixed with NADH (at 1:1 mole ratio) with 0.78 
mg/ml FBS and titrated concentrations of sodium bicarbonate buffer (0.00-1.50 mg/ml). Coomassie Blue stained 
SDS-PAGE with βME present (G), or lacking βME (H) Au3+ mixed with NADH (at 1:1 mole ratio) with 0.78 mg/ml 
FBS and titrated concentrations of sodium bicarbonate buffer (0.00-1.50 mg/ml). For G and H the concentrations of 
sodium bicarbonate are from 0.00 – 1.50 mg/ml from left to right after the ladder proteins. Plot of the ratio of the 







   
formation by 80% from non-buffered synthesis, however, if through the addition of this buffer we 
are able to better maintain protein integrity, this can be an acceptable loss of production efficiency. 
To explore the potentially protein-protective capacities of synthesis in buffered solution we 
reintroduced FBS protein (at 0.78 mg/mL) to our buffer titrated synthesis to observe protein 
integrity through Raman spectroscopy and SDS-PAGE (±β-Me) (Figures 26D-I). From Raman 
spectroscopy we observed two prominent peaks within all concentrations of buffer (Figures 26D). 
These peak intensities decreased proportionately to the concentration of buffer (Figures 26E), 
however, the ratios of the major to minor peak intensities increased with an apparent linear 
relationship with the buffer concentration (Figures 26F). The decrease in overall Raman intensity 
as the buffer concentration increases corresponds to the decrease in relative plasmon formation 
and are both in correspondence with the notion that increased concentrations of buffer will result 
in lower efficiency nanoparticle formation. However, the presence of major and minor amide peaks 
found through Raman spectroscopy only in buffered synthesis is indicative that there exists a 
potentially protein preservation property which does not exist in non-buffered synthesis. To 
investigate this potential protein preservation as well as protein-nanoparticle adhesion, we 
employed Coomassie stained SDS-PAGE (±β-Me) (Figures 26G and H). From (+)β-Me 
Coomassie Blue stained SDS-PAGE we are able to see a darkening in the main FBS protein band 
as well as reduction of streaking/fragmentation as the concentration of buffer used in synthesis 
was increased (Figures 26G).  We were able to quantify this relationship between protein integrity 
and buffer concentration, by first plotting the pixel intensity of the gel lanes as a function of 
distance (normalizing the plots to the brightest band on the gel and the background intensity of the 
area between wells). From these plots we can identify four landmarks to characterize protein 
integrity, main FBS peak intensity, average lane intensity, proximal-well intensity (large protein), 
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and distal-well intensity (small protein). To plot the ratio of proximal:distal well intensity as a 
function of buffer concentration gives us information as to how the size of protein fragments 
transitions from small  large as the concentration of buffer is increased. When the ratio of the 
main FBS band to the average well intensity is plotted as a function of buffer concentration it 
reveals that the amount of FBS protein protected from fragmentation is increased as buffer 
concentration is also increased (Figures 26I). When compared with (-)β-Me Coomassie stained 
SDS-PAGE of FBS-functionalized GNP synthesis with titrated buffer, we observe (1) a decrease 
in the darkness intensity for the nanoparticle region of the gel, (2) a decrease in protein streaking 
and background intensity, and (3) a decrease in the intensity of small distally migrating protein 
bands/ fragments as the concentration of the buffer is increased. These three trends observed are 
abruptly changed for the synthesis with the highest concentration of buffer (1.5 mg/ml), where we 
are able to observe an increased intensity for the nanoparticle region, as well as some resurgence 
in the main FBS band intensity. This resurgence of nanoparticle and FBS band intensity in the 
synthesis with the highest buffer concentration could indicate that either the FBS protein is no 
longer adhered to formed gold nanoparticles and this enables the nanoparticle migration through 
the gel or that at this buffer concentration the FBS protein is so significantly maintained that excess 
unbound protein is maintained, aggregation from degraded protein is not formed, and that 
nanoparticles formed within non-aggregated protein enables their migration through the gel. We 
found no particular trends in nanoparticle morphology through TEM at various concentrations of 
buffer (Figure 27). After optimizing FBS-gold nanoparticle formation via NADH reduction to 
maintain the FBS protein integrity, we then aimed to compare cellular impact against other one-
step synthesis for forming FBS bound gold nanoparticles which either require pH modification, or 
heating. Using ICP-MS, we were able to compare the internalization efficiency of FBS-bound gold 
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nanoparticles through various synthetic methods (Figure 28A). Our synthetic method involving 
NADH, FBS, and ionic gold without buffer proved to be more effective for cellular internalization 
than our buffered version, both of which were more effective than methods utilizing pH 
modification and heating. nanoparticles functionalized with FBS via heating or pH modification 
were either less effective or comparable with controls (Figure 29A) of gold nanoparticles reduced 
with NADH without FBS, or ionic gold admixed with FBS without reduced nanoparticles. The 
internalization effeciency of these gold containing treatments is also reflected through the impact 
on cellular viability (Figure 28B and Figure 29B). From this metabolic activity assay we see that 
nanoparticles which are internalized by the lowest fraction have the lowest impact on cellular 
viability and that treatments which are internalized the most have the highest impact on cellular 
viability.  
Figure 27 TEM images of Au3+ mixed with NADH (at 1:1 mole ratio), 0.78 mg/ml FBS and 0.30 (A), 0.60 (B), 0.75 






   
We would also use stain-free flow cytometry (at IC50 concentrations as determined by MTT), 
comparing forward and side-scattered light, to observe how our treatments would potentially 
disrupt the distribution of cell size and complexity or if it would cause fragmentation/ or cell lysis 
to occur. To ascertain physical impacts of our treatment, we would plot flow cytometry results in 
a dot plot, comparing our treatments against positive and negative controls similar to those used 
for MTT and ICP-MS. From these treatments, we found a shift in forward-scatter and side-scatter 
toward lower intensities for all treatments in varying degrees compared with the no treatment 
(Figure 28C). The FBS-GNP synthesis involving pH modification resulted in the most dramatic 
population shift compared with the other treatments, then NADH (non-buffered), and heating, 
followed by the NADH synthesis in buffered solution. This indicated that the FBS-GNP synthesis 
involving pH modification had the largest impact, reducing size and complexity of the affected 
cells then NADH (non-buffered), heating, and then followed by the NADH synthesis in buffered 
solution.  
Figure 28 Percentage of gold internalization by ICP-MS (A), impact on cell viability (B), and comparisons of 






   
 
3.3.8 SINGLE-STEP SYNTHESIS OF MEMBRANE BOUND GOLD NANOPARTICLES IN 
BUFFERED SOLUTION 
Having optimized a single step synthesis of gold nanoparticles wherein proteins in solution are 
bound and the integrity of said proteins are better maintained as well as characterizing the cellular 
impact of the application of these nanoparticles we next aimed to apply this knowledge directly to 
whole cell membrane. Within the cell membrane, there exist a complex multitude of biomolecules 
involved in cellular signaling and communication.161–164 Among these cell membrane derived 
attributes exists the properties of cell-cell adhesion; homotypic cell adhesion, cells adhering to 
cells of the same type or heterotypic cell adhesion, cells adhering to cells of a different type. This 
balance of hetero/homotypic cell adhesion is deterministic of tissue and organoid formation, as 
Figure 29 Percentage of gold internalization by ICP-MS (A), impact on cell viability (B), and comparisons of 






   
well as cancer progression towards metastasis.76–79 These homotypic adhesion properties have 
been usitilized by other researchers to delivery targeted therapeutics to cancers.68,70,165 Many of 
these research papers utilize B16F10 cells for their homotypic properties and we would do as well, 
so that we are able to compare our single step process against tried benchmarks.   We would collect 
B16-F10 cell membrane fragments through tip sonication followed by differential centrifugation, 
separate and collect the organic soluble portion of this membrane in chloroform to form thin-films. 
We would then rehydrate these thin films, adding energy via tip sonication to form membrane 
vesicles. For generating nanoparticles within cellular membrane, ionic gold was added during the 
rehydration step, and reduction action either through pH modification, or NADH would be 
introduced after forming the membrane vesicles. From DLS we found a slight shift in the 
hydrodynamic diameter with the formation of nanoparticles within the membrane vesicles (Figure 
30A) and through TEM observe gold nanoparticle formation within clusters of protein (Figure 
30B). From SDS-PAGE (Figure 30B), we confirm that membrane protein will degrade almost 
entirely in the presence of Au3+ without buffer, that these proteins can be maintained in gold 
nanoparticle reduction via NADH and that many of these proteins are adherent to the formed gold 
nanoparticles. To characterize cellular impact of these nanoparticles generated within cellular 
membrane derived vesicles, we would compare against synthesis processes which either utilize pH 
modification to reduce gold nanoparticles or utilize reduced gold nanoparticles coated with an 
aminated surface functionality acting as an adhesive surface (linker) for the cellular membrane. 
Through ICP-MS we were unable to detect internalized gold for either of these synthetic processes 
which either use pH modification or linker molecules  while the process utilising NADH in 
buffered solution resulted in an internalization of 1.6 ± 0.3 % of the treatment dosage.   
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Figure 30 Hydrodynamic diameter of membrane vesicles and membrane vesicles with GNPs reduction (A). TEM 
of membrane vesicles with GNP formation (B) via NADH in buffer with magnification right and filtration (bottom). 
SDS-PAGE with Coomassie Blue staining of protein ladder, B16-F10 cell membrane, B16-F10 cell membrane mixed 
with ionic gold, B16-F10 cell membrane vesicles with GNP reduction via NADH and buffer with βME or without 
βME (from left to right respectively. Cell viability of membrane bound GNPs formed through various synthetic 





   
The internalization effeciency of these gold containing treatments is also reflected through the 
impact on cellular viability (Figure 30D). From this metabolic activity assay we see that 
nanoparticles which are not quantifiably internalized have the lowest impact on cellular viability 
and that treatments which are internalized the most have the highest impact on cellular viability. 
We also observed this trend through stain-free flow cytometry (at IC50 concentrations as 
determined by MTT), comparing forward and side-scattered light. From these treatments, we 
found a shift in forward-scatter and side-scatter toward lower intensities for all treatments in 
varying degrees compared with the no treatment (Figure 30E). gold nanoparticles generated 
within cellular membrane derived vesicles with buffer and NADH resulted in the most dramatic 
population shift compared with the other treatments, then the linker, followed by the pH based 
synthesis. This indicated that the gold nanoparticles generated within cellular membrane derived 
vesicles with buffer and NADH had the largest impact, reducing size and complexity of the 









In summary, we have demonstrated the capacity and utility of nanoparticles generated from 
endogenous biomolecules through three examples which can potentially be applied to multitudes 
of applications 
1. Through a point of care reactive gel, acting as a scaffold for ionic gold (Au3+) capable 
of sensing reductive biomolecules presented in high concentrations during eye injury. 
2. The generation of gold nanoparticles intrecellularly for enhanced phenotype 
observation of the cell combined with therapeutic potential.  
3. A simplistic, single-step means of generating gold nanoparticles functionalized with 
whole cell membrane which imparts minimal impact on biomolecule integrity. 
Clinical significance for the detection of a penetrating ocular injury. Unfortunately, an easy method 
of identifying ocular penetrating injuries is not always readily available. It can be difficult to 
identify an injury that has fully penetrated the globe even in a hospital setting. A biosensor that 
provides a rapid test to determine if the eye is intact to allow for appropriate triage, evacuation, 
and subsequent vision saving treatment can be potentially transformative. In this work we have 
developed and demonstrate a new reactive plasmonic based biosensing material composed of ionic 
gold interspersed through agarose gel scaffolding. Upon interaction with endogenous reductive 
molecules such as AA in eye fluid, the OjoGel undergoes colorimetric changes in a quantifiable 
manner dependent on the concentration of the reductant molecules. We have demonstrated this 
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quantifiable colorimetric relationship with AA in solutions of varied complexity, including clinical 
samples. In demonstrating the capacity of the OjoGel to determine AA concentration in water, 
contrived tear film, and aqueous humor collected from clinical samples, we have confirmed that 
the OjoGel can be utilized to provide rapid quantitative detection of biologically relevant markers, 
like AA. With further improvement in its basic eye fluid collection device, this platform can be 
easily developed as a commercial product with better user supplier interface for patient care. Use 
of this approach may mitigate vision loss by improving the accuracy of diagnosis, and allow more 
efficient use of medical resources saving healthcare cost. Additionally to this, we have 
demonstrated a simplistic nano-scaled delivery system combining ionic gold and PEG, which 
enables the progressive reduction and formation of plasmonic gold nanoparticles that are both 
fluorescent and capable of photothermal heating for ablative therapies. We have characterized this 
process through the identification of associated proteins combined with their entailing molecular 
processes and subcellular locations. We have determined that our process does not destroy the 
integrity of associated proteins and additionally, compared with previous applications, requires 
considerably lower concentrations of ionic gold and time.  We envision future applications, 
propelling the next major advancement in nanomedicine, wherein the treatment focuses on fluid-
form small molecules which form nanostructures en route. These envisioned fluid-form treatments 
will utilize and rely on cellular machinery dependent on the local histopathology of the tissue 
providing highly specific opportunities for sensing, therapy, or control over local physiology. 
Lastly, we have developed a single step process for generating biomolecule functionalized gold 
nanoparticles in a single step wherein, the biomolecule integrity is maintained. This process, which 
is reliant on NADH in buffered solution, requires no heating, pH modification, or synthetic 
molecules and can be applied to either homogeneous (FBS) or complex (whole membrane) 
 
88 
   
biomolecule systems to generate biomolecule-functionalized gold nanoparticles. This builds off of 
the previous stand-alone observation, that NADH can reduce gold,166 through its utilization in this 
streamlined synthesis process. We found that NADH as reductant for gold nanoparticles will result 
in relatively uniform, monodisperse nanoparticles (13 ± 3 nm) at a range of concentrations and 
reactant ratios. However, the active site of NADH, being susceptible to oxidation via acidic 
conditions, results in divergent morphological conformations of the nanoparticles when the 
synthetic mixture is at or near the equivalency pH of NADH. Additionally to the active site of 
NADH, cellular biomolecules (namely proteins) proved susceptible to degradation in acidic 
conditions, however this could be mitigated through use of buffering the solution. The results of 
this work implicates a major streamline for the generation of biofunctionalized theranostic 
plasmonic metal nanoparticles. 
 
4.2 FUTURE AIMS 
From this body of works we have demonstrated that multitudes of endogenous biomaterials have 
the capacity to reduce and form nanoparticles by variety of mechanisms. We have demonstrated 
the direct benefit to sensing pathological states, applying therapy, as well as a means for 
improvement on previous biomimetic theranostics. To further each of these technologies, the 
identification of specific pathological systems which could most benefit from these processes must 
be identified, and the general principles of utilizing endogenous biomaterials applied to other 
therapeutic processes and design parameters. Doing so will greatly advance the field of 
personalized medicine wherein the therapeutic or diagnostics are developed utilizing patient 
derived materials.  
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APPENDIX A: METHODS 
 
Unless stated otherwise, all material and reagents were purchased from Sigma–Aldrich 
and were used without further purification. 
  
Synthesis of Ojogel 
The gold (III) chloride-agarose gel (2% OjoGel) was developed by dissolving 23.1 mg of gold (III) 
chloride hydrate 99.99% salt in 2.271 ml of de-ionized water (DI water) to obtain a final 
concentration of 30 mM. Then 1mL of 30 mM gold (III) chloride solution was mixed with 160 mg 
of agarose powder in 4 mL of DI water in a 20 ml disposable scintillation vial. The total solution 
of 5mL was then heated in a microwave for 90 seconds. The hot solution was immediately 
transferred into centrifuged tubes and a capillary tube was placed to create a small channel in the 
middle of the gel. The solution was allowed to solidify at room temperature (RT) for around 30 
minutes and was later stored at 4 C until further use.     
 
Quantification of  Gold (III) Chloride Reduction and Correlation to Ascorbic Acid 
Concentration 
In order to find out the reducing activity of ascorbic acid on gold (III) chloride solution to form 
gold nanoparticles we conducted a series of trials in which we took pictures with a normal 
cellphone. At first, we made standard AA solution with concentrations of 2,000μM, 1,000μM, 
500μM, 250μM, 125μM, and 50μM. The standards, are then delivered to the channel created in 
the gel with help of another capillary glass tube to get some color change which is indicative of 
reducing activity of ascorbic acid on gold (III) chloride solution. The gels showed different color 
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changes when reacted with samples of different concentrations. To establish a scale, we put the 
reacted PCR tubes together in a PCR stand. A number of pictures (50) were taken for each 
concentration from one side with the varying distance of a flash light. An app (Pixel Picker® 
available on Apple App Store™) was used to figure out the RGB value in the color changed areas. 
We did the same statistics for 50 pictures and found the average of the RGB values for each color 
changed area. Then we restore a color sequence based on the calculated RGB average and correlate 
it with the standard concentration of AA. Based on this optimized information, a color code ring 
was developed with assigned shade of color representing a nomimal gold reduction and related 
ascorbic acid concentration. OjoGel tubes were placed in these color rings before capturing snaps 
of changed color in OjoGel tubes. Color changes were co-related with used ascorbic acid 
concentration.    
 
Ascorbic Acid Detection Using Commercial ELISA Kit.  
The ELISA experiments were performed using a 96-well plate. Six known concentrations (0, 2, 4, 
6, 8, 10 nmol) of ascorbic acid and five human aqueous humor samples (1−5) with unknown 
ascorbic acid concentration were pipetted into the microliter plate wells with a volume of 120 µl 
(Ascorbic Acid/Aqueous Humor Sample Plus Ascorbic Acid Assay Buffer) of each sample. 30 µl 
of catalyst was then added to each standard and sample well. After 15 min incubation at RT (18-
25 °C), 50 µl of the reaction mix was added to each well containing the AA Standard and test 
samples. A color (pink) is developed within 3 min and stable for an hour. After 30 min, each well 
was then measured for 2s in a Spectrophotometer with Gen 5.0 software at 490nm OD. 
Measurements were tested in duplicate sets, and the average value was then utilized to determine 
the final ascorbic acid concentration. 
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Specificity Study of AA Detection Using OjoGel 
Specificity study was performed by using OjoGel tubes incubated with AA and other major 
components of eye fluid including L-Lactic acid and Sialic acid. Experiment was performed on 2 
mM concentration by incubating for 5 min at RT. Results of reduced OjoGel tubes was acquired 
from Pixel Picker® app on mobile phone. A total of 25 pictures were used to compare the results. 
 
Sensitivity Study of AA Measurements Using OjoGel 
Sensitivity of OjoGel tubes in DI-H2O and contrived tear film was evaluated by correlating RGB 
hexadecimal values obtained from different concentration of AA incubated with OjoGel tubes. 
First order derivative of R hexadecimal values was plotted on log scale for R/AA and concentration 
of AA to achieve sensitivity plot. Parameters of sensitivity were derived from plot by 
extrapolation.  
 
Dynamic light scattering  
Hydrodynamic diameters were determined using a Malvern Zetasizer ZS90 particle size 
analyzer, while scattered light was collected at a fixed angle of 90°. A photomultiplier aperture of 
400 mm was used, with the incident laser power adjusted to obtain a photon counting rate between 
200 and 300 kcps. Measurements for which the measured and calculated baselines of the intensity 
autocorrelation function agreed to within +0.1% were used to calculate hydrodynamic diameter 
values. Hydrodynamic diameter was analyzed using number distribution in accordance with 
various previous reports. All determinations were made in multiples of 3 consecutive 




Au-PEG cluster synthesis  
In a 20 ml scintillation vial, 0.015 mmoles of HAuCl4 and 500 mg of PEG (Mn=10,000 g/mol) are 
mixed in a sealed glass vial with 2 ml of carbon filtered deionized water (0.2 µm cellulosic 
membrane, pH = 4). This mixture was incubated in a 37 °C water bath for 30 minutes before being 
diluted 100 fold with carbon filtered deionized water (0.2 µm cellulosic membrane, pH = 7). 
 
Na-PEG cluster synthesis  
In a 20 ml scintillation vial, 0.015 mmoles of NaCl and 500 mg of PEG (Mn=10,000 g/mol) are 
mixed in a sealed glass vial with 2 ml of carbon filtered deionized water (0.2 µm cellulosic 
membrane, pH = 4). This mixture was incubated in a 37 °C water bath for 30 minutes before being 
diluted 100 fold with carbon filtered deionized water (0.2 µm cellulosic membrane, pH = 7). 
 
Transmission electron microscopy measurements (TEM) 
For TEM, 2.5 μL of the as-prepared Au-PEG clusters were placed on a 300-mesh carbon film 
supported by a copper grid and allowed to stabilize for 2 min. A filter paper was then used to 
remove liquid for thin liquid films formation and then allowed to air dry while covered. Images 
were obtained using a Jeol 2010 cryo-electron microscope operating at 200 kV, and using different 
degrees of defocus to obtain an adequate bright contrast. Images were recorded on a Gatan 
UltraScan 2kx2k CCD. These CCD images were processed and analyzed with ImageJ 




Scanning electron microscopy (SEM) and electron dispersion spectroscopy (EDS) 
For SEM-EDS, several 3 μL drops of the as-prepared Au-PEG clusters were placed on a strip of 
copper tape placed on an SEM sample grid and allowed to stabilize for 5 min. A filter paper was 
used to remove liquid for thin liquid films formation and then allowed to air dry while covered. 
Images were obtained using a Hitachi S4700 scanning electron microscope with Oxford 
Instruments ISIS EDS X-ray Microanalysis System. SEM images were captured using a 10 kV 
accelerating voltage, a 10 μA emission current, and a 12 mm working distance, adjusting sample 
height for coarse focus and low degrees of defocus to obtain secondary electron images and EDS. 
Images were recorded using a Centaurus BSE detector. 
 
UV-VIS absorption studies 
For collecting the UV-VIS spectra, 1mL of the as-prepared Au-PEG clusters were used. For 
calibration, the blank consisted of carbon filtered deionized water (0.2 µm cellulosic membrane, 
pH = 7). The absorption spectra were acquired in scanning mode for the range of 200-1000 nm 
using a GeneSys 10S UV-Vis Spectrophotometer (Thermo Scientific, Rockford, IL). 
Measurements were taken at every 0.1 nm interval.  
 
Human transform cell culture 
MCF-7 cells (ER (+) human breast cancer cells) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma) supplemented with 10% fetal bovine serum (FBS) and 1x Penstrep in 
T25 culture flasks (Cellstar; Germany) and were incubated at 37 °C in a 99% humidified 
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atmosphere containing 5% CO2. Cells were regularly passaged by trypsinization with 0.1% trypsin 
(EDTA 0.02%, dextrose 0.05%, and trypsin 0.1%) in DPBS (pH 7.4). Non-synchronized cells were 
used for all the experiments. 
 
Cell growth inhibition studies with MTT assay  
MCF-7 cells were seeded at 10,000 cells/well in DMEM with 10% FBS and 1x Penstrep (200 
μL/well) in a 96-well plate and incubated at 37 °C in a 99% humidified atmosphere containing 5% 
CO2 for 24 hours. Cell treatments were as follows: Control, Na-PEG, Nifuroxazide-PEG, Au-PEG, 
and Au3+   Each treatment of the cells had concentrations 0.05 - 0.6 mM. After treatment, cells 
were incubated for 44 hours.  After 44 hours, 20 μL MTT solution (5 mg/mL Thiazolyl Blue 
Tetrazolium Bromide) was added to each well and the plate was incubated for an additional 4 
hours.  Media was then aspirated from each well and 200 μL dimethyl sulfoxide (DMSO) was 
added.  The plate absorbance was then read at 570 nm wavelength using Gen5 Microplate Reader 
and Imager Software. For investigating the reaction with ionic gold and Thiazolyl Blue 
Tetrazolium Bromide, identical concentrations were used, without cells.     
 
Cell culture treatment with Au-PEG clusters for transmission electron microscopy 
Samples of Au-PEG were diluted in full cell media to 0.24 mM Au3+ by mixing 0.5 ml Au-PEG 
clusters with 15 ml cell media. After removing old media, this mixture would incubate on a 
monolayer of MCF7 cells (grown in T-25 flasks until ~80% confluency) growing at 37 °C with 
5% CO2 for 4 hrs. After this incubation period, growth medium was discarded and cell monolayer 
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was washed with DPBS before trypsinizing the treated cells. Cells were harvested in small 1.5 mL 
centrifuge tubes and collected in DPBS before fixing using Karnovsky's Fixative. After the cell 
pellet was fixed in a Karnovsky's Fixative in phosphate buffered 2% Glutaraldehyde and 2.5 % 
Paraformaldehyde. Microwave fixation was used with this primary fixative, and the tissue is then 
washed in Sorenson’s phosphate buffer with no further additives. Microwave fixation was also 
used with the secondary 2% Osmium Tetroxide fixative, followed by the addition of 3% Potassium 
Ferricyanide for 30 minutes. After washing with water, saturated Uranyl Acetate was added for 
enbloc staining. The tissue was dehydrated in a series of increasing concentrations of ethanol. 
Acetonitrile was used as the transition fluid between Ethanol and the Epoxy. Infiltration series was 
done with an epoxy mixture using the epon substitute Lx112. The resulting blocks were 
polymerized at 90 ºC overnight, trimmed and ultrathin sectioned with diamond knives. Sections 
were stained with Uranyl Acetate and Lead Citrate and examined or photographed with a Hitachi 
H600 Transmission Electron Microscope at 75KV. 
 
Enhanced darkfield hyperspectral imaging 
Optical and hyperspectral images were captured at 60x magnification under enhanced darkfield 
illumination using the CytoViva hyperspectral imaging system (Auburn, AL). This hyperspectral 
imaging system couples an enhanced dark-field illuminator with optical and hyperspectral CCD 
cameras. 
The hyperspectral images, also called datacubes, were collected using the “push broom” method. 
The spectral data (400 – 1000 nm) was acquired one pixel row at a time. The acquisition was 
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facilitated by a motorized stage. The hyperspectral analysis software ENVI compiled this spectral 
and spatial data into a datacube, in which each pixel contained spectral data. 
Spectral libraries corresponding to the reduced gold nanoparticles were built from the images of 
exposed MCF-7 cells. These libraries were filtered against a negative control image (cells only, 
Supplemental Figure 1) to ensure no false-positive mapping of the nanoparticles. Using the 




Control treatments with Au-PEG clusters 
Both 150 µl of as-prepared Au-PEG clusters and 250 µl of media either fresh orhaving been used 
to incubate cells for ~24 hours (‘spent’ media)were admixed in a 2 ml microcentrifuge tube and 
incubated in a water bath for 24 hours. From these samples, 2.5 µl would be extracted for TEM 
analysis as described in the TEM measurements section. 
2ml of as-prepared Au-PEG clusters were added to an empty poly-L-lysine treated culture plate. 
This container was incubated at 37 °C in a 99% humidified atmosphere containing 5% CO2 for 24 






Cell culture treatment with Au-PEG clusters for Raman spectroscopic analysis 
Samples of Au-PEG were diluted in full cell media to 0.24 mM Au3+ by mixing 0.5 ml Au-PEG 
clusters with 15 ml cell media. After removing old media, this mixture would incubate on a 
monolayer of MCF7 cells (grown on glass slides until ~80% confluency) growing at 37 ºC with 
5% CO2 for 4 hrs. After this incubation period, growth medium was discarded and cell monolayer 
was washed with DPBS before fixing with 37% Formaldehyde solution. Raman spectra were 
acquired on cells incubated with Au-PEG treatment and on control cells lacking treatment in 
reflection mode (LabRAM HR 3D Horiba confocal microscope). Laser light was focused through 
a 100x, NA 0.8 objective into the sample plane and the scattering was collected in the reflection 
geometry using the spectrograph coupled with an Andor Newton back-illuminated EMCCD 
camera. The excitation wavelength for the measurements was set to 633nm, and the power was set 
to 8 mW at the sample with a 0.2s acquisition time. Raman shift from 1000 to 3050 cm–1 was 
collected at 8 cm–1 spectral resolution. Intensities of select vibrational modes were selected to 
generate the Raman images.  
 
Cell fractionation of treated cells  
Samples of Au-PEG were diluted in full cell media to 0.24 mM Au3+ by mixing 0.5 ml Au-PEG 
clusters with 15 ml cell media. After removing old media, this mixture would incubate on a 
monolayer of MCF7 cells (grown in T-25 flask ~80% confluency) growing at 37 °C with 5% CO2 
for 4 hrs. The cells were then trypsinized and centrifuged at 20,000 x g to form a cell pellet. The 
trypsin was removed, and the pellet suspended in 1.5 ml DPBS before tip sonication (5 s on, 2 s 
off at 1 amp for 2 min) was used to rupture the cells. Ruptured cells were separated into cell 
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fractions following the exact protocol as described by Lodish et al.167 Using an Eppendorf 
(Hamburg, Germany) 5424 R microcentrifuge for centrifugation speeds lower than 100,000 x g, 
and a Beckman Coulter (Indianapolis, IN) Optima MAX-XP Ultracentrifuge for speeds above 
100,000 x g. Pelleted fractions were suspended in 1 ml DPBS (pH 7.4) before SDS-PAGE or 
Raman analysis. SDS-PAGE and Raman samples were prepared immediately after fractionization. 
 
 
Raman spectroscopic analysis of cell fractions 
Raman measurements were taken using a Nanophoton Raman instrument at Frederick Seitz 
Materials Research Laboratory Central research facilities, UIUC (532 nm laser). For each 
spectrum, a grating (600mm-1) scan was taken over the range of 1000–3000 cm-1 at 0.2% laser 
power for one minute (20x objective). An average of 20 spectra was recorded and averaged per 
sample.  
 
SDS-PAGE analysis of cell fractions 
A BioRad Mini-PROTEAN® Tetra Vertical Electrophoresis Cell was loaded with 2x 5-20% 
gradient Mini-PROTEAN gels and the electrophoresis cell filled to the appropriate fill line with 
1x Tris/Glycine SDS buffer. Two portions of nuclear protein fractions from cells treated with Au-
PEG, Na-PEG, or untreated were admixed with 4x Laemmli sample buffer (BioRad) either 
containing 2.5% β-mercaptoethanol or with 1x Tris/glycine SDS buffer in the same volume with 
pipetting to addmix. From these six prepared protein samples 20 µl was added to wells 2-4 and 6-
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8, with five µl of Precision Plus (10-250 kDa) protein ladder in lanes 5 and 9. After allowing the 
samples to settle in their respective wells for 5 minutes the cover of the electrophoresis cell was 
added, power turned on to 200V and allowed to run approximately 35 minutes (the dye front < 1 
cm from the edge of the gel). For LC-MS, the nuclear fraction extracted from cells treated with 
Au-PEG were allowed to run for >3 hours (until all of the ladder proteins had run off the gel) 
without protein from other cell treatments. 
 
Coomassie Blue total protein stain 
Gel was briefly rinsed with DI H2O before being immersed in protein fixing solution (10% Acetic 
acid, 10% Methanol, in Di H2O) for 30 minutes with gentle rocking. After fixing for 30 minutes, 
the gel was stained with 1x Coomassie Blue staining solution (BioRad) for 2 hours with gentle 
rocking. After staining, the gel was submerged in destaining solution (10% acetic acid in DI H2O) 
for 24 hours, replacing the destaining solution as it became saturated with residual Coomassie 
stain. After the gel was adequately destained, a BioRad gel-dock imaging system was used to 
image the stained gel. The images were contrast enhanced, and band intensities analyzed with 
ImageJ. 
 
Protein Extraction via passive elution and LC-MS analysis 
 Nuclear fractions from MCF-7 cells treated with Au-PEG which had been allowed to run through 
gel electrophoresis for >3 hrs.  The top portion of the gel containing the wells of the gel (the top 
1.5 cm) were excised from the bulk of the gel with a scalpel and placed into separate 15 ml 
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centrifuge tubes. The gel pieces were ground inside their respective containers with sterile cleaned 
metal weighing spatulas before mixing with minimal elution buffer (50 mM Tris-HCl, 150 mM 
NaCl, and 0.1 mM EDTA; at pH 7.5), but ensuring that the gel pieces were completely immersed. 
These immersed gel fragments containing protein were incubated at room temperature on a rocker 
for 48 hours. After this, samples were centrifuged at 5,000 g for 10 min before removing the 
supernatant for submission to the Roy J. Carver Biotechnology Center (CBC) for LC-MS analysis 
via partial trypsinization digestion. 
 
Inhibitor Study 
A T-175 flask of MCF7 cells at 80% confluency was split and plated (at equal cell density) into 
15 T-25 culture flasks. Cells were grown for 24h before being incubated with different endocytic 
inhibitors. Inhibitor formulations were made with reconstituted medium having sodium azide and 
deoxyglucose (NaN3), CPM (chlorpromazine), nystatin and dynasore at a concentration of 10 μM, 
50 μM, 28 μM, 180 nM and 80 μM, respectively, which were used as described in some previous 
reports 2–4Cells were incubated with inhibitors for 1h at ambient condition. Inhibitors were then 
replaced with Au-PEG diluted in full cell media to 0.24 mM Au3+ by mixing 0.5 ml Au-PEG 
clusters with 15 ml cell media.. All the treatments were performed in triplicate. Cells treated with 
ionic Au-PEG clusters in absence of inhibitors were used as control. After the required incubation 
time of 4h, cell pellets and supernatants were collected for each sample and subjected to further 





Flow Cytometry analysis 
To further characterize the cytotoxicity of our ionic gold delivery platform, we performed flow 
cytometry analysis. Cells (MCF-7, 10000 cells/well) were grown in 24 well plate for 24 h before 
treating with different samples prepared for this study for 4h. At the end of incubation cells were 
trypsinized and collected in 0.2% FBS containing DPBS. Samples were analyzed using a Guava 
EasyCyte Plus Flow cytometer. For each sample, data from 5000 single cell events were collected 
for 3 minutes, in triplicates, and forward scatter vs side scatter information were recorded. The 
results were analysed and plotted using Flowpy. 
 
Animal Studies 
To investigate potential theranostic applications pre-clinically we would generate and treat MCF-
7 xenograft tumors in J/NU immunodeficient double knockout mice. The experimental protocol 
was approved by the Institutional Animal Care and Use Committee (IACUC), University of 
Illinois, Urbana–Champaign, and satisfied all University and National Institutes of Health (NIH) 
rules for the humane use of laboratory animals. All the animal experiments were carried out in 
accordance with the approved guidelines. J/Nu mice were bought from Jackson Laboratories, 
U.S.A. Upon arrival mice were allowed 2 weeks for acclimation. Animals were group housed with 
free access to food and water with individuality marked through ear punching. With 12 mice we 
would inject 10^6 cells in matrigel on the flanks of the mouse with one injection per side. From 
this, 16 tumors grew to usable size (~5x5 mm2). Of these injections 16 tumors grew to usable size. 
There were five mice with two tumors, six with only one, and one mouse which did not have any 
tumors of usable size.  These 16 tumors would receive intratumoral injections of either Na-PEG 
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or Au-PEG. No mouse with two tumors would receive identical treatment injections on both 
tumors.  These tumors injected with either Au-PEG or Na-PEG would receive photothermal 
ablative therapy using 500 mW 633 nm continuous wave laser for 5 min (+laser) or 0 min (- laser) 
periods with IR camera (FLIR technologies) to monitor and quantify the temperature changes.  
From these groups we would have four tumors with Na-PEG injections and 0 min of laser 
treatment; three tumors with Na-PEG injections and 5 min of laser treatment; four tumors with 
Au-PEG injections and 0 min of laser treatment; five tumors with Au-PEG injections and 5 min 
of laser treatment. For all tumors which were destroyed by the ablation therapy, treatments were 
no longer made for those mice. Injections of 40 µl were administered using 32g syringe needles 
over 2 minutes under isoflurane anesthesia (2.5 mg/l flow rate) with an oxygen flow rate of 1 l/hr. 
 
IVIS Imaging Studies 
Animals were imaged individually at 1, 24, 48 72, and 168 hours after injections were administered 
with 430 nm excitation and 840 nm emission wavelengths. Animals which receive photothermal 
ablative therapies were imaged at these same time points and additionally 30 minutes after laser 
treatment (1.5, and 24.5, and 48.5 hours). During imaging, animals were anesthetized with 
isoflurane (2.5 mg/l flow rate) with an oxygen flow rate of 1 l/hr. 
 
Photothermal ablative therapy with IR-Imaging 
Photothermal ablative therapy was applied using 500 mW 633 nm continuous wave laser 
(RLTMRL-635-500-5, Roithner Lasertechnik) for 5 min (+laser) or 0 min (- laser) periods with 
IR camera (FLIR technologies) to monitor and quantify the temperature changes. Upon completion 
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of the laser therapy, a neutral density filter with 100% OD was placed in front of the beam, 
blocking the path of the laser. See supplemental figure S11 for laser stand setup. An iPad mounted 
IR-camera (FLIR Technologies) was used to obtain snapshot thermal images of photothermal 
applications at 2.5 min into laser application.  Temperature maxima for these images were 
considered as photothermal treatments representative of surface temperature. During photothermal 
treatments and IR-imaging animals were anesthetized with isoflurane (2.5 mg/l flow rate) with an 
oxygen flow rate of 1 l/hr. 
 
Histology sectioning 
At the end of the experiment, animals were sacrificed via isoflurane saturation. Organ tissue were 
immediately excised and frozen in tissue cassettes withoptimal cutting temperature (OCT) 
compound from tumors, sentinel lymph nodes, liver, kidneys, and spleen. Embedded tissue blocks 
were clamped in microtome and sectioned at 6 μm thickness. Tumor and sentinel lymph node 
slices were either left unstained (Raman mapping) or Hematoxylin and eosin (H&E)stained (bright 
field imaging). 
 
Raman Mapped Histology 
Tissue sections, left unstained, were imaged in the reflection mode via LabRAM HR 3D Horiba 
confocal microscope with 532 nm wavelength excitation laser with power set at 8mW. The laser 
light was focused through a LWD Visible 20x, NA 0.40, objective into the sample plane and 
scattering was recorded in the reflection geometry using a spectrograph coupled with an Andor 
123 
 
Newton back-illuminated EMCCD camera. An acquisition time of 1 s was used. The Raman shift 
from 310 to 3,410 cm–1 was recorded with a spectral resolution of 3 cm–1. 
NADH nanoparticle synthesis 
In a 1 ml microcentrifuge tube, volumes less than 50 µl of 104.0 mg/ml of HAuCl4 and 93.6 mg/ml 
NADH were admixed at 1:1 mole ratios at concentrations of NADH from 0.36 – 17.60 mM, then 
with 6 µl of 93.6 mg/ml NADH  varying the mole ratio of Au3+ : NADH (0.0 – 4.0). all of these 
reactions were balanced with carbon filtered deionized water maintaining total volume of 1 ml.  
The reduction of Au3+ by NADH occurred at room temperature with shaking to mix. 
Fourier transform infrared spectroscopy (FTIR) 
An aqueous suspension of the samples was dried onto a MirrIR IR-reflective glass slides (Kelvey 
Technologies, Chesterland, Ohio, USA) for Fourier Transform Infrared (FT-IR) measurements 









B16F10 Cell culture 
B16F10 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma) 
supplemented with 10% fetal bovine serum (FBS) and 1x Penstrep in T25 culture flasks (Cellstar; 
Germany) and were incubated at 37 °C in a 99% humidified atmosphere containing 5% CO2. Cells 
were regularly passaged by trypsinization with 0.1% trypsin (EDTA 0.02%, dextrose 0.05%, and 
trypsin 0.1%) in DPBS (pH 7.4). Non-synchronized cells were used for all the experiments. 
Collecting cell membrane 
B16F10 cells were lifted through trypsinization and centrifuged at 20,000 x g to form a cell pellet. 
The trypsin was removed, and the pellet suspended and washed in DPBS,  followed by washing in 
molecular grade ultrapure water, before resuspension in molecular grade ultrapure water 
(hypotonic to enhance cell lysis) before tip sonication (QSonica, Newton, CT ) to rupture the cells. 
Tip sonicator settings were: 5 s on, 2 s off at 1 amp for 2 min. The cell membrane fragments were 
isolated from ruptured cells using differential centrifugation following the protocol as described 
by Lodish et al.167  Using an Eppendorf (Hamburg, Germany) 5424 R microcentrifuge for 
centrifugation speeds lower than 100,000 x g, and a Beckman Coulter (Indianapolis, IN) Optima 
MAX-XP Ultracentrifuge for speeds above 100,000 x g. Non-membrane cellular components were 
discarded, cell membrane fragments were resuspened in ultrapure molecular grade water and 
lyophilized for at least a day.  
Single-Step FBS protein functionalized nanoparticle synthesis 
In a 1 ml microcentrifuge tube, volumes less than 6 µl of 104.0 mg/ml HAuCl4 would be admixed 
with 10.4 mg/ml FBS balanced with carbon filtered deionized water for a final volume of 994 µl 
for concentrations of FBS in solution ranging from 0.00 – 2.60 mg/ml. This solution was allowed 
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to stabililize for no greater than 10 min before admixing of 6 µl of 93.6 mg/ml NADH were added 
with mixing to reduce nanoparticles. The reduction of Au3+ by NADH occurred at room 
temperature with shaking to mix. The concentrations of HAuCl4 and NADH as well as volumes 
were modified in order to accommodate mole ratio variations for synthesis. 
 
Single-Step FBS protein functionalized nanoparticle synthesis in titrated buffer 
In a 1 ml microcentrifuge tube, volumes less than 6 µl of 104.0 mg/ml HAuCl4 were added to 34 
µl 10.4 mg/ml FBS balanced with carbon filtered deionized water with sodium bicarbonate buffer 
(1.5 mg/ml) and carbon filtered deionized water without buffer for a final volume of 994 µl for 
concentrations of sodium bicarbonate ranging from 0.0-1.5 mg/ml. to this 6 µl of 93.6 mg/ml 
NADH were added with mixing to reduce nanoparticles. The reduction of Au3+ by NADH occurred 
at room temperature with shaking to mix. The concentrations of HAuCl4 and NADH as well as 
volumes were modified in order to accommodate mole ratio variations for synthesis. 
Single-Step Membrane coated nanoparticle synthesis   
Lyophilized cell membrane of known mass was admixed with chloroform to make a final 
concentration of 11.7 mg/ml cellular membrane in chloroform. From this solution 100 µl would 
be dispensed into glass culture tubes in order to form thin films via chloroform evaporation. Thin 
films were rehydrated with 988 μL of either ultrapure molecular biology grade water or ultrapure 
molecular biology grade water with added sodium bicarbonate (1.5 mg/ml) and 0 or 6 μl of HAuCl4 
(104.0 mg/ml). Rehydrated films were tip sonicated (QSonica, Newton, CT ) to induce vesicle 
formation (settings as 5 s on, 2 s off, 1 amp, for 2 min). To these vesicles, either 0 or 6 μl of NADH 
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(93.6 mg/ml) or 3 drops of 10% N NaOH were added to induce nanoparticle reduction and the 
sample was tip sonicated again (same settings) to promote homogeneity.  
 
Multi-Step Membrane coated nanoparticle synthesis using a linker molecule  
Lyophilized cell membrane of known mass was admixed with chloroform to make a final 
concentration of 11.7 mg/ml cellular membrane in chloroform. From this solution 100 µl would 
be dispensed into glass culture tubes in order to form thin films via chloroform evaporation. Gold 
nanoparticles would be formed via NADH reduction in a 1.5 ml centrifuge tube by admixing 6 μl 
of HAuCl4 (104.0 mg/ml) with 6 μl of NADH (93.6 mg/ml) in 902 μl of ultrapure molecular 
biology grade water. To these nanoparticles 86 μl of 3-aminopropane-1-thiol hydrochloride (1.3 
mg/ml) was added as a linker molecule forming a positively charged animated surface for the 
cellular membrane to adhere to similar as used by Parodi et al.73 This solution of gold nanoparticles 
would be used to hydrate B16F10 cellular membrane thin film and this thin film would then receive 
two tip sonication sessions (settings as 5 s on, 2 s off, 1 amp, for 2 min). 
 
 
 
 
 
 
